[go: up one dir, main page]

WO2018181380A1 - Edible composition for intestinal bacteria - Google Patents

Edible composition for intestinal bacteria Download PDF

Info

Publication number
WO2018181380A1
WO2018181380A1 PCT/JP2018/012545 JP2018012545W WO2018181380A1 WO 2018181380 A1 WO2018181380 A1 WO 2018181380A1 JP 2018012545 W JP2018012545 W JP 2018012545W WO 2018181380 A1 WO2018181380 A1 WO 2018181380A1
Authority
WO
WIPO (PCT)
Prior art keywords
dietary fiber
edible composition
enteric bacteria
intestinal
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/012545
Other languages
French (fr)
Japanese (ja)
Inventor
伸周 浦壁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advance KK
Original Assignee
Advance KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advance KK filed Critical Advance KK
Publication of WO2018181380A1 publication Critical patent/WO2018181380A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731Carrageenans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734Alginic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/22Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/888Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962Allium, e.g. garden onion, leek, garlic or chives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998Hordeum (barley)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to an edible composition for intestinal bacteria constituting intestinal flora (intestinal flora).
  • the present invention also relates to a health food containing such an edible composition for enteric bacteria and a method for producing the same.
  • Non-Patent Document 1 research on intestinal flora is progressing and elucidating.
  • Non-Patent Document 1 research on intestinal flora is progressing and elucidating.
  • Obesity is not necessarily caused by over calories, but is caused by fat cell hypertrophy. Enterobacteria produce short-chain fatty acids that eliminate obesity, but as mentioned above, enterobacteria themselves have deteriorated due to westernization of their diet, etc., so the ability to produce short-chain fatty acids is reduced, Obese patients continue to increase.
  • the short-chain fatty acids produced by the intestinal flora stimulate the intestinal cells and promote the secretion of an incretin hormone that works to secrete insulin from the pancreas, but the deterioration of the intestinal flora is the production of short-chain fatty acids. Since the amount is decreased, the amount of insulin secreted is reduced, which causes diabetes.
  • Obesity increases the number of Ariake, one of the enteric bacteria.
  • Ariake senescent cells (irreversible cell growth arrest induced by constant activation of the cell cycle checkpoint mechanism when normal cells undergo irreparably large DNA damage)
  • DCA deoxycholic acid
  • cancer such as liver cancer, breast cancer, and esophageal cancer
  • “Equol” is a substance produced by intestinal bacteria eating soy components (isoflavones), and also a substance that keeps skin healthy, and works similar to female hormones, but the intestinal flora that produces this is The number of humans (permanent in about half of Japanese people) is decreasing year by year. Since equol binds to the estrogen receptor, it suppresses the stimulation of the mammary gland by excessively secreted estrogen, reducing the probability of breast cancer, but when equol decreases, the number of estrogen bound to the estrogen receptor Is believed to increase the chances of over-stimulating the mammary gland and causing breast cancer.
  • Equol suppresses the activation of the male hormone testosterone to become dihydrotestosterone, prevents excessive dihydrotestosterone, and binds to dihydrotestosterone and inhibits binding to the androgen receptor. It has the action of suppressing androgen that causes prostate cancer. With the reduction of “equol”, prostate cancer is thought to increase as well.
  • Degradation of the intestinal flora reduces the amount of short-chain fatty acids that are produced, causing the immune cells (leukocyte T cells) that cause allergies to run away. That is, immature leukocyte T cells are changed to regulatory leukocyte T cells (T-leg cells) by butyric acid (short chain fatty acid). T-reg cells suppress the activity of mature leukocyte T cells and suppress excessive reaction (runaway) of leukocyte T cells, but as the intestinal flora deteriorates, the production of short chain fatty acids decreases, Since leukocyte T cells that change to T-leg cells also decrease, the activity of leukocyte T cells becomes uncontrollable and runaway, increasing allergies and autoimmune diseases.
  • the macrophages such as leukocytes react with the toxins outside the intestinal tract by secreting inflammatory cytokines, and the whole body is light. It becomes inflamed. Due to this prolonged inflammation, macrophages such as leukocytes become hypersensitive and leukocytes that begin to attack by phagocytosing so-called foreign substances that have not been attacked until now, resulting in dead leukocytes that are insufficiently digested and digested by foreign substances The macrophages accumulate and cause arteriosclerosis.
  • Intestinal flora produces neurotransmitters that nerve cells use in transmitting stimulus signals.
  • Neurotransmitters include “serotonin”, “dopamine”, and the like, which are responsible for mind and body stability, will and improvement.
  • the neurotransmitter produced by the intestinal flora stimulates the brain directly via vagus cells, and as a result, the amount of neurotransmitter produced decreases with the deterioration of the intestinal flora, causing depression and other mental disorders. It becomes.
  • toxin 4EPS 4-ethylphenyl sulfate
  • Intestinal flora is thought to dominate the brain by its product.
  • the number of human genes is 23,000, which is not much different from Daphnia, mice, etc., whereas the intestinal flora that normally resides in the intestine has 12 million genes, 99% of the necessary metabolites are produced by the intestinal flora.
  • Intestinal flora synthesizes and produces vitamin K, a blood clotting component that humans cannot make. Deterioration of the intestinal flora reduces the amount of blood clotting components produced, which can make hemostasis difficult.
  • Intestinal flora produces folic acid, vitamin B12, which forms red blood cells, and is responsible for human life activities. Deterioration of the intestinal flora reduces the amount of folic acid and vitamin B12 produced and lowers the ability to form blood cells, which may cause cerebral anemia and mental illness. And so on.
  • JP-A-61-5022 discloses the relationship between intestinal flora and biological activity, and enterococcus bacteria useful for humans such as Enterococcus faecalis dead cells and Enterococcus lactobacilli, Bifidobacterium. It is described that there is a proliferation effect. JP-A-61-5022 and related scientific publications at that time make handling of intestinal bacteria, which can be provided only with pharmaceuticals, more complicated than live bacteria and more familiar.
  • Japanese Patent Application Laid-Open No. 3-151854 discloses that a mixture of oligosaccharides and soluble dietary fiber can reduce enterobacterium harmful fungi Clostridium genus and Escherichia genus.
  • JP 2012-111771 A discloses a dietary fiber preparation as a food or pharmaceutical product containing partially hydrolyzed guar gum (PHGG), wherein the second soluble fiber contains fructooligosaccharide (FOS) and has improved prebiotics ability. Is disclosed.
  • JP-T-2016-505533 discloses a grain as an ingredient that may be used in Chinese medicine such as whole grains, beans, nuts, peanuts, corn (eg, yellow corn, white corn, red corn, purple corn, etc.).
  • JP 2011-501940 discloses a bacterium of bifidobacteria (bifidobacterium) by containing a ternary mixture of a viscous water-soluble fiber, a non-viscous water-soluble fiber, and a water-insoluble fiber.
  • Food compositions that increase the number and reduce the number of pathogenic bacteria (such as coliforms and Salmonella) have been disclosed.
  • Japanese Patent Application Laid-Open No. 2005-154388 discloses an intestinal function improving agent containing cyclofructan, which is a cyclic inulooligosaccharide composed of fructose molecules cyclically linked by ⁇ -2,1 bonds, as an active ingredient. .
  • Japanese Patent Application Laid-Open No. 2007-320946 describes that enterococcus faecalis, Lactobacillus reuteri and whey, root kelp, and other natural food powders are combined to increase the growth of useful bacteria and reduce harmful bacteria. ing.
  • Japanese Patent Publication No. 2014-513965 discloses that a dietary fiber composition such as fructooligosaccharide, indigestible dextrin, and polydextrose can be used to lengthen the fermentation period of dietary fiber in the large intestine and realize a comfortable bowel movement. Is disclosed.
  • Non-patent document 2 shows that when lactose and inulin are increased by 20 g / day and then ingested for 19 days, intestinal bacterial environment and bowel movement are improved.
  • Non-patent document 3 describes that the pH of feces was lowered by ingestion of inulin-containing cereal meal.
  • JP-A-2016-172761 describes improvement of bowel movement with a composition containing inulin, indigestible dextrin, lactulose and the like, as in Non-Patent Document 1.
  • JP-A-61-5022 Japanese Patent Laid-Open No. 3-151854 JP 2012-111171 A Special table 2016-505533 Special table 2011-501940 gazette JP 2005-154388 A JP 2007-320946 A Special table 2014-513965 gazette JP 2016-172761 A
  • “Diversity” of intestinal flora indicates, for example, the number of types of intestinal bacteria. “Increase” means, for example, the growth and activation of intestinal bacteria, which is a function of the intestinal flora that has been lost in the past due to the increase in the amount of defecation or deterioration of the intestinal flora. Or may include regaining functionality that may be needed.
  • the function of intestinal bacteria has many unexplained functions
  • the diversity shown in the present invention is the type of intestinal bacteria that produce useful substances such as short-chain fatty acids and equol, and their intestines. It may be preferable to show an increase in the intestinal flora formed by the internal bacteria.
  • enterobacteria that have a certain role for humans, even in the case of enterobacteria that are generally classified as genus Clostridium and Escherichia. In some cases, the increase in the presence of bacteria can be shown as the diversity of enteric bacteria.
  • the diversity of intestinal flora may indicate a variety of beneficial intestinal bacteria, or a balanced state of harmful bacteria, useful bacteria, and opportunistic bacteria.
  • the present invention has been made in view of the above, and as a result of earnest research on the relationship between enterobacteria, which are now elucidated, and humans, It is not the so-called “natural movement theory” that humans make use of intestinal flora, but intestinal flora makes use of humans, that is, the intestines that human health is protected only after the health of intestinal flora is created.
  • the inventor has arrived at the present invention by finding that the inner flora should be based on the so-called “ground motion theory”.
  • the present invention relates to an edible composition
  • an edible composition comprising a dietary fiber and / or an enterobacterial hot water extract that can be eaten stably or without resistance by human beings, which are mainly eatable by intestinal bacteria. Realize the provision of (food).
  • Examples of the foods eaten by the intestinal bacteria and the intestinal flora include dietary fiber.
  • the intestinal flora shown in the present invention is a collection of intestinal bacteria, but when explaining its functionality, it shows the functionality of the intestinal bacteria alone.
  • dietary fiber examples include dietary fiber alone or natural or synthetic foods containing dietary fiber.
  • Ingredients are preferably natural or naturally derived in that enteric bacteria and intestinal flora increase diversity and produce many effective products.
  • Dietary fiber includes both water-soluble dietary fiber and water-insoluble dietary fiber.
  • the dietary fiber shown in the present invention includes either or both of synthetic dietary fiber and naturally-occurring dietary fiber, but the synthesized dietary fiber lacks the functions and components of the naturally-derived dietary fiber.
  • digestive absorption in the body is not sufficient, and natural dietary fiber may be preferred because it may not be a preferred food (assistant) for intestinal bacteria and intestinal flora.
  • the dietary fiber in the present invention is, for example, a composition in which enterobacteria are fermented and absorbed in the intestinal tract, that is, an enterobacterial food (utilized product), wherein the intestinal bacteria are short-chain fatty acids.
  • enterobacteria are fermented and absorbed in the intestinal tract
  • an enterobacterial food utilityized product
  • the intestinal bacteria are short-chain fatty acids.
  • Examples of foods that produce short-chain fatty acids include naturally derived inulin, but those purified and extracted from chicory, chrysanthemum, burdock, leek, etc., and raw material components of chicory root, chrysanthemum, burdock, and leek Therefore, a natural extract containing a predetermined amount (for example, 70% or more) of inulin is more preferable in that it has sufficient natural dietary fiber capacity and can be obtained at a lower cost.
  • a predetermined amount for example, 70% or more
  • the dietary fiber related to the fruit can also increase the diversity of the intestinal flora in the same manner as the natural dietary fiber, and as a whole can be an assimilated composition suitable for the intestinal flora. .
  • “Stable” includes not only eating at regular intervals every day, but also to the extent that it is possible to eat even if it is a single shot, and to eat again.
  • enteric bacteria such as food additives
  • it is preferable not to use as much as possible degradation factors of enteric bacteria such as food additives if there is a bitter taste or a unique texture or taste of other ingredients themselves, more uniform mixing of ingredients and granulation This makes it possible for humans to eat stably.
  • short-chain fatty acids produced by intestinal bacteria prevent fat cell hypertrophy and eliminate obesity, and thus prevent liver cancer, breast cancer, esophageal cancer, etc. caused by obesity, and regulatory T cells.
  • To increase the production ability of the leukocytes suppress the runaway of white blood cell T cells that cause allergies, improve the barrier function of the intestines, and prevent leaking intestines.
  • the “leaking intestine” is a decrease in the ability of the intestinal bacterium to produce short-chain fatty acids due to the deterioration of the intestinal bacterium, thereby reducing the intestinal barrier function and creating a gap in the intestinal tract.
  • leukocytes and macrophages attack the leaked toxins and bacteria in the blood, the whole body becomes mildly inflamed, inhibiting insulin activity and stimulating intestinal cells.
  • dead bodies such as leukocytes accumulate in the blood vessels and cause arteriosclerosis.
  • the present invention has realized providing an edible composition containing foods of enteric bacteria that promotes the production of short-chain fatty acids by making enteric bacteria healthy and increasing diversity. .
  • Short chain fatty acids are composed of acetic acid, propionic acid, butyric acid, their esters, and their salts, and are mainly produced by intestinal flora.
  • the present invention is intended to compensate for the production of short chain fatty acids in intestinal flora. In some cases, short-chain fatty acids may be added separately.
  • enterobacterial foods that produce short-chain fatty acids include inulin as described above, and examples of natural inulin-containing materials include chicory, chrysanthemum, burdock, and leek. It is.
  • the extract of chicory root is particularly preferable in that it contains a large amount of inulin derived from nature, and is superior in absorbability and functionality compared to synthesized inulin.
  • Synthetic dietary fibers generally have stronger adsorption capacity than natural ones, and use natural inulin because there is a risk that minerals necessary for humans may be discharged outside the body. It may be preferable.
  • the present invention provides an increase in the diversity of intestinal flora by providing a substance that can be ingested stably by humans, which is a substance that is mainly consumed by enterobacteria to activate intestinal flora. Is realized.
  • the present invention comprises 25 to 70% (preferably 40% to 50%) of chicory root powder and chrysanthemum powder with respect to the total weight, fruit components
  • examples include 10-50% (preferably 25% -40%), buckwheat, guar gum which is a thickener and dietary fiber, and enterobacterial bacterial powder. Is done.
  • guar gum used as a thickener, it is preferable to use other natural gums that function as dietary fibers.
  • the chicory root extract is rich in inulin, which is a water-soluble dietary fiber, and is suitable for increasing fecal excretion efficiency.
  • Chicory is a herb-based vegetable and, depending on the degree of extraction, has characteristics of bitter ingredients such as lactupirin, flavor, and fragrance.
  • bitter ingredients such as lactupirin, flavor, and fragrance.
  • the present invention after powdering these, add fruit powder, and by mixing uniformly and granulating, the natural origin such as bitterness It is possible to provide a composition that can relax a unique taste and can be stably eaten by humans.
  • a fluidized bed granulation method is preferable, and a powdered food that has good uniformity of granulation components and is bitter and can be eaten mellowly and stably can be formed.
  • Inulin includes synthetic inulin obtained by enzymatic synthesis using sugar as a raw material, as well as naturally-derived inulin extracted from chicory, chrysanthemum, etc., but synthetic inulin is inexpensive and highly pure. From the nature, it is thought that there is a problem that it is difficult to be assimilated by intestinal bacteria because it is considered that the components derived from nature are insufficient and the digestive absorption in the gastrointestinal tract is poor. In contrast, naturally-occurring inulin may be affected by the weather and yield, and the quality may not be stable, but it can maintain the original components of inulin and is well absorbed by the body. It is thought that it is excellent in utilization.
  • the inulin derived from chrysanthemums is not suitable for long-term storage because it contains components that degrade inulin in the chrysanthemum salmon itself.
  • a chicory root extract is preferred as the component to be increased.
  • ⁇ -glucan fructan, albinoxylan, konjac glucomannan, hemicellulose (soy polysaccharides, rice bran, brown rice, corn hulls), polydextrose, lignin, High methoxy pectin, oligosaccharide: raffinose, stachyose (galacto-oligosaccharide) fructooligosaccharide, maltotriose, maltotetraose, maltopentaose, fucoidan (seaweed such as mekabu, kelp, mosque), water-soluble soybean polysaccharide, pullulan, etc.
  • the dietary fiber may increase the diversification of intestinal flora, so it may be included in an edible composition that humans eat stably.
  • the present invention is a food effective for enterobacteria, preferably a naturally occurring dietary fiber that can be stably eaten by humans, Enterococcus faecalis AD101 (FERM P-20739), Lactobacillus reuteri AD302 ( FERM P-20741) and an edible composition containing a hot water extract (dead cells) of Lactobacillus acidophilus AD206 increases the diversity of intestinal flora, thereby realizing human health.
  • enterobacteria preferably a naturally occurring dietary fiber that can be stably eaten by humans
  • Enterococcus faecalis AD101 FERM P-20739
  • Lactobacillus reuteri AD302 FERM P-20741
  • an edible composition containing a hot water extract (dead cells) of Lactobacillus acidophilus AD206 increases the diversity of intestinal flora, thereby realizing human health.
  • natural dietary fiber that enteric bacteria prefer to eat dietary fiber components such as chicory, chicory root extract, chrysanthemum, etc., fruit with a taste that can be eaten stably by humans, etc. It is preferable that the edible composition is a combination of both dietary fibers.
  • the chicory, chicory root extract or chrysanthemum pod in the present invention contains a lot of inulin, is eaten by intestinal bacteria, and is decomposed into short chain fatty acids. Since chrysanthemums contain ingredients that degrade inulin, securing an effective amount of inulin requires purified extraction and may lack naturalness. Suitable as food.
  • Inulin can absorb sugar in the body because it takes in sugar in the process of becoming a swollen gel when it contacts water. Therefore, by increasing the amount of inulin to 4 g or more as shown in the examples, the range of taste as a food can be widened, and it is easy for humans to take and can be taken daily.
  • an inulin-containing natural food ingredient has been shown as a main component as an embodiment of the present invention
  • Natural foods and extracts thereof containing water-soluble dietary fiber such as indigestible dextrin, resistant starch, fucoidan, water-soluble soybean polysaccharide, pullulan and their degradation products may be used.
  • a granulated product may be formed by combining flavor-adjusting dietary fiber materials for realizing a taste, flavor, and texture that can be eaten stably.
  • the intestinal bacterial hot water extract in the present invention represents a hot water extract (dead cell) of Enterococcus faecalis AD101 (FERM P-20739), Lactobacillus reuteri AD302 (FERM P-20741), and Lactobacillus acidophilus AD206. .
  • FERM P-20739 Enterococcus faecalis AD101
  • Lactobacillus reuteri AD302 (FERM P-20741)
  • Lactobacillus acidophilus AD206 Lactobacillus acidophilus AD206.
  • JP-A-61-5022 and JP-A-2007-320946 they exhibit the ability to grow useful bacteria, and in combination with natural dietary fiber, It is possible to further increase the diversity of internal bacteria.
  • Examples of the hot water extraction method include the method shown in JP-A-61-5022.
  • a powder using a fluidized bed granulation method with a uniform particle size and capable of mixing the uniform components may be further granulated, made into a capsule shape, a sugar coating shape, or an aqueous solution shape. Further, it may be processed into sprinkles, soft drinks, biscuits, rice crackers and the like.
  • Enterococcus faecalis AD101 (FERM P-20739) and Lactobacillus reuteri AD302 (FERM P-20741) are deposited at the Patent Biological Depositary Center based on their respective deposit numbers.
  • Example 1 shown in Table 1 shows that chicory root extract (90% inulin) is 20% based on the total weight%, chrysanthemum pod 5.2%, oat 6%, guar gum 3%, apple, mango, A powder consisting of 32% fruit components containing dietary fiber such as banana, etc., is a food that is eaten by intestinal bacteria by removing the bitterness inherent in chicory by uniform powdering by fluidized bed granulation technique, An edible composition that can be stably eaten by humans is produced.
  • guar gum 3% of the total weight
  • a fluidized bed flow generator spraying hot air from the lower side of the raw material powder in the granulation chamber while spraying it.
  • the particles are granulated while fluidizing them on a rotating plate to form powders or granules having uniform particle diameters and components.
  • This granulation method uniformly mixes chicory root extract, fruit components, etc. to produce powders or granules having a more uniform particle size. Therefore, the taste unique to chicory root is alleviated and eaten by humans.
  • chicory root extract was used as inulin, but it may be extracted from chrysanthemum extract, other burdock, and leek, but is preferable for assimilation of intestinal bacteria, To increase diversity, increase the amount of defecation as much as possible without using synthetic food additives as much as possible (10g-30g a day), and the stability of the product for continuous use Because it is preferably maintainable, chicory root extract is preferred for intestinal bacteria and intestinal flora with high inulin content.
  • chicory Since chicory has a bitter component, it can be finely pulverized and then mixed uniformly with dietary fiber components with sweetness such as other fruits using a fluidized bed granulation method. It becomes a health food that can contribute to the assimilation of intestinal bacteria while suppressing additives, and that can be continuously received by humans.
  • Example 2 in Table 1 has approximately twice the amount of chicory root extract compared to Example 1.
  • these powders form a uniform state and are suitable for humans to continuously eat foods of intestinal bacteria while suppressing bitterness. Can be obtained.
  • Example 1 10 g of powdered or granulated food prepared by pulverizing these ingredients (Example 1) is taken as a single intake, eaten as it is, or dissolved in milk, water, etc. Ingest about 5 times. Since humans eat a considerable amount of dietary fiber such as inulin, the intestinal microflora eats these naturally-derived inulin-containing foods that reach the intestines, generating short-chain fatty acids and increasing the amount of defecation The effect of short-chain fatty acids is demonstrated by improving the activity of the intestinal flora, but the sensory test on the ingredients shown in Example 1 having a uniform particle size and powder as a component, and a granular powder food According to the results of (10 test subjects), although there are some sweetnesses, there are many respondents with 8 people that the bitterness and flavor peculiar to chicory are suppressed and that they have a mellow texture. More than half of the products were evaluated as foods without resistance. As for the improvement and frequency of bowel movements, 7 to 8 people
  • composition of Example 4 Soybean hypocotyl extract (extract) powder 10% Guar gum 3% Fruit juice component powder (dietary fiber) 70% Enterococcus faecalis AD101 (deposit number P-20739) 2.82% Lactobacillus reuteri AD302 (deposit number P-20741) 0.2% Lactobacillus acidophilus AD206 0.1% Others (honey powder, etc.) 13.88% Total 100%
  • Example 3 uses barley as dietary fiber, and fruit juice fiber and other components are fruit fibers such as banana, apple and mango, and honey and the like are shown as in Examples 1 and 2. .
  • Enterococcus faecalis AD101 (deposit number P-20739), Lactobacillus reuteri AD302 (deposit number P-20741), and hot water extract (dead cells) of Lactobacillus acidophilus AD206, as described above, have the ability to grow useful resident bacteria. Therefore, it has a function to further increase the diversity of intestinal bacteria resident in the intestine.
  • Barley endosperm portion contains a large amount of water-soluble dietary fiber ⁇ -glucan and, like inulin, has the function of increasing the diversity of intestinal bacteria and increases the amount of feces.
  • the barley (endosperm) powder is preferably obtained by separating the barley endosperm portion.
  • the barley flour is extracted by hot water extraction and solid separation, or air separation or sieving.
  • buckwheat (oat) may be used as in Examples 1 and 2.
  • barley powder, fruit juice component powder, etc. are made into powder or granules having a uniform component and particle size by using a fluidized bed granulation technique using guar gum.
  • Example 4 contains about 10% to 50% soy hypocotyl extract powder containing a large amount of isoflavone, which is a raw material for producing equol in the intestine. Soybean hypocotyl extract has bitterness, sashimi, etc., so as to alleviate this and improve the taste and texture, use food additives as much as possible, and further adjust dietary fiber components such as fruit juice components
  • the added powder is mixed and a powder or granule having a uniform particle size and components is formed by a fluidized bed granulation technique.
  • Soybean hypocotyl extract also relieves bitterness compared to the hypocotyl itself, but in order for humans to eat stably, it is preferable to have a mellow texture that further reduces bitterness.
  • the powder blended with fruit dietary fiber has a more uniform particle size and a uniform component, so that the taste becomes mellow and can be continuously eaten.
  • Example 5 an intake test was performed according to the following procedure. For 20 subjects who showed constipation symptoms and were treated for atopy and other diseases, powdered foods having the ingredients shown in Example 2 of Table 1 were ingested daily (from 1st to several days). Then, after ingestion, a questionnaire survey was conducted on each subject for subsequent bowel movements.
  • the edible composition for enteric bacteria according to appendix 1 wherein the dietary fiber is one or more members selected from the group consisting of inulin, ⁇ -glucan, lecithin, fructan, and guar gum.
  • the dietary fiber is selected from the group consisting of powder of natural cereal material consisting of burdock, leek, chrysanthemum, chicory, barley, buckwheat or guar gum or powder thereof and banana, apple, mango or peach fruit powder.
  • the dietary fiber is one or more members selected from the group consisting of fucoidan, fructooligosaccharide, arabinoxylan, hemicellulose, levan, soybean oligosaccharide, and konjac glucomannan, and is extracted from natural foods.
  • the edible composition for enteric bacteria according to appendix 1.
  • the dietary fiber includes naturally occurring galactooligosaccharides, fuco-oligosaccharides, manno-oligosaccharides, xylo-oligosaccharides, sialyl-oligosaccharides and other oligosaccharide compositions, fructan, galactan, fucoidan, arabinan, xylan, xanthan, galacturonan, N-glycan Includes one or more members selected from the group consisting of, ⁇ -glycan, hyaluronic acid, chondroitin, xyloglucan, arabinogalactan, alginate, carrageenan, galactomannan, arabinoxylan, glycolipid glycan, glycoprotein glycan, and proteoglycan
  • the edible composition for enteric bacteria according to appendix 1, wherein the extracted natural food or an extract obtained by extracting the natural food is included.
  • the present invention relates to dietary fiber suitable for intestinal flora to eat (utilize) and the heat of Enterococcus faecalis AD101 (deposit number P-20739), Lactobacillus reuteri AD302 (deposit number P-20741), and Lactobacillus acidophilus AD206.
  • Enterococcus faecalis AD101 deposit number P-20739
  • Lactobacillus reuteri AD302 deposit number P-20741
  • Lactobacillus acidophilus AD206 By providing an edible composition containing an aqueous extract (dead cells) in a form that is easy for humans to take, the diversity of intestinal flora in the human body can be increased, thus providing new health Provide food.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)

Abstract

To provide an edible composition for intestinal bacteria which ameliorates intestinal flora (intestinal bacterial flora) and promotes the diversity thereof so as to contribute to human health. A composition comprising: a natural dietary fiber component, said natural dietary fiber component being eatable by intestinal flora and having preferable taste and flavor so that humans can take the same continuously; and hot water-extracts (dead cells) of Enterococcus faecalis AD101(FERM P-20739), Lactobacillus reuteri AD302 (FERM P-20741) and Lactobacillus acidophilus AD206. The composition preferably comprises, as a main component, a powdery or granular product obtained by homogeneously mixing an extract of Cichorium intybus with other dietary fibers such as fruits.

Description

腸内細菌用可食性組成物Edible composition for enterobacteria

 本発明は、腸内フローラ(腸内細菌叢)を構成する腸内細菌のための可食性組成物に関する。本発明はまた、かかる腸内細菌用可食性組成物を含む健康食品及びその製造方法に関する。 The present invention relates to an edible composition for intestinal bacteria constituting intestinal flora (intestinal flora). The present invention also relates to a health food containing such an edible composition for enteric bacteria and a method for producing the same.

 食生活の欧米化の浸透により脂肪や砂糖の摂取量が増えた反面野菜の消費量が激減し、腸内フローラが食する食物繊維の摂取量は50年前の半分以下となっている。
 また、病院や、歯科医院などで多用される抗生物質は、人の体内に残留し、腸内フローラにダメージを与え、食用のウシ、ブタ、ブロイラー等に使われる抗生物質、食品添加物、農薬、水道水の塩素成分等も、腸内フローラにダメージを与えている状況がある。
 食品添加物は、その種類によっては、ヒトにとって無害でも、腸内細菌にとっては、ダメージを与えるものもある。
While the intake of fat and sugar has increased due to the penetration of Western diets, the consumption of vegetables has drastically decreased, and the intake of dietary fiber consumed by intestinal flora has fallen below half that of 50 years ago.
Antibiotics frequently used in hospitals and dental clinics remain in the human body, damage the intestinal flora, and are used for edible cattle, pigs, broilers, etc., food additives, pesticides There are also situations where the chlorine component of tap water damages the intestinal flora.
Depending on the type of food additive, some food additives are harmless to humans, but some are harmful to intestinal bacteria.

 その結果、人の糞便量も減少し、腸内フローラも糞便量の減少した分だけ減少すると共に上述したダメージを受けて腸内環境が悪化している状況がある。
 食生活の変化は、同時に動脈硬化、心臓病、糖尿病等のいわゆる生活習慣病を増加させ、高齢化と共に、医療費を増加させている。
As a result, the amount of human feces is reduced, the intestinal flora is reduced by the amount of reduced fecal amounts, and the intestinal environment is deteriorated due to the damage described above.
Changes in dietary life simultaneously increase so-called lifestyle-related diseases such as arteriosclerosis, heart disease, diabetes, etc., and medical costs are increasing with aging.

 他方で、腸内フローラに関する研究が進行し、解明が進められている(非特許文献1)。例えば、研究の結果、次のような効果や影響、可能性などが見いだされるに至っている。 On the other hand, research on intestinal flora is progressing and elucidating (Non-Patent Document 1). For example, as a result of research, the following effects, influences, and possibilities have been found.

 1.肥満は、必ずしもオーバーカロリーが原因ではなく、脂肪細胞の肥大化により生じる。腸内細菌は、肥満を解消させる短鎖脂肪酸を生成するが、上述したように食生活の欧米化等により腸内細菌自体が劣化しているために、短鎖脂肪酸の生成能が低下し、肥満患者は増え続ける一方である。
 又、腸内フローラが生成する短鎖脂肪酸は、腸の細胞を刺激して、膵臓からインスリンの分泌を働きかけるインクレチンというホルモンの分泌を促すが、腸内フローラの劣化は、短鎖脂肪酸の生成量を減少させるため、インスリンの分泌量が少なくなり、糖尿病の原因となる。
1. Obesity is not necessarily caused by over calories, but is caused by fat cell hypertrophy. Enterobacteria produce short-chain fatty acids that eliminate obesity, but as mentioned above, enterobacteria themselves have deteriorated due to westernization of their diet, etc., so the ability to produce short-chain fatty acids is reduced, Obese patients continue to increase.
In addition, the short-chain fatty acids produced by the intestinal flora stimulate the intestinal cells and promote the secretion of an incretin hormone that works to secrete insulin from the pancreas, but the deterioration of the intestinal flora is the production of short-chain fatty acids. Since the amount is decreased, the amount of insulin secreted is reduced, which causes diabetes.

 2.腸内細菌の劣化に伴う短鎖脂肪酸の生成量の減少は、腸管のバリア層の劣化につながり、腸管に隙間(漏れる腸)を生じさせる。この腸管の隙間から腸内の有害な細菌、毒素が腸管外部へ放出される。腸管外に漏れ出した毒素等に対し白血球等のマクロファージが炎症性サイトカインを分泌するなどして反応し、全身が軽い炎症状態となる。
 炎症状態となった細胞組織付近でインスリンの働きが低下する為、糖尿病の原因となる。
2. A decrease in the amount of short-chain fatty acids produced due to deterioration of the intestinal bacteria leads to deterioration of the barrier layer of the intestinal tract, causing a gap (leaking intestine) in the intestinal tract. Harmful bacteria and toxins in the intestine are released to the outside of the intestine through the gaps in the intestine. Macrophages such as leukocytes react with toxins leaking outside the intestinal tract by secreting inflammatory cytokines, etc., and the whole body is in a mild inflammatory state.
Insulin is reduced in the vicinity of inflamed cell tissues, causing diabetes.

 3.肥満により腸内細菌の一つであるアリアケ菌が急増する。アリアケ菌は、細胞を老化(正常細胞に修復不可能なほど大きなDNAダメージが生じた場合に、細胞周期チェックポイント機構が恒常的に活性化することで誘導される不可逆的な細胞増殖停止状態)させ、肝臓ガン、乳ガン、食道ガン等の癌を誘発する物質であるDCA(deoxycholic acid)を体内に増加させる。 3. Obesity increases the number of Ariake, one of the enteric bacteria. Ariake senescent cells (irreversible cell growth arrest induced by constant activation of the cell cycle checkpoint mechanism when normal cells undergo irreparably large DNA damage) DCA (deoxycholic acid), which is a substance that induces cancer such as liver cancer, breast cancer, and esophageal cancer, is increased in the body.

 4.「エクオール」は、大豆成分(イソフラボン)を腸内細菌が食べて生成する物質であり、肌の健康を保つ物質でもあり、女性ホルモンと似た働きを示すが、これを生成する腸内フローラを持つヒト(日本人の約半分に常在)が年々減少している。「エクオール」は、エストロゲン受容体と結合するため、過剰に分泌されたエストロゲンによる乳腺の刺激を抑制し、乳ガンになる確率を低くするが、エクオールが減少すると、エストロゲン受容体にエストロゲンが結合した数が増加する為、乳腺を過剰に刺激し、乳ガンになる可能性が高まると考えられている。又「エクオール」は男性ホルモンであるテストステロンが活性化してジヒドロテストステロンとなることを抑制し、 ジヒドロテストステロン過多を防止すると共に、ジヒドロテストステロンと結合して、アンドロゲン受容体と結合することを抑制することから、前立腺ガンの原因となるアンドロゲンを抑制する作用がある。
 「エクオール」の減少により、前立腺ガンも同様に高まると考えられている。
4). “Equol” is a substance produced by intestinal bacteria eating soy components (isoflavones), and also a substance that keeps skin healthy, and works similar to female hormones, but the intestinal flora that produces this is The number of humans (permanent in about half of Japanese people) is decreasing year by year. Since equol binds to the estrogen receptor, it suppresses the stimulation of the mammary gland by excessively secreted estrogen, reducing the probability of breast cancer, but when equol decreases, the number of estrogen bound to the estrogen receptor Is believed to increase the chances of over-stimulating the mammary gland and causing breast cancer. "Equol" suppresses the activation of the male hormone testosterone to become dihydrotestosterone, prevents excessive dihydrotestosterone, and binds to dihydrotestosterone and inhibits binding to the androgen receptor. It has the action of suppressing androgen that causes prostate cancer.
With the reduction of “equol”, prostate cancer is thought to increase as well.

 5.腸内フローラの劣化により、生成される短鎖脂肪酸が減少し、アレルギーの原因となる免疫細胞(白血球T細胞)が暴走する。
 即ち、未成熟の白血球T細胞は、酪酸(短鎖脂肪酸)により制御性白血球T細胞(Tレグ細胞)に変化する。Tレグ細胞は、成熟した白血球T細胞の活動を抑制し、白血球T細胞の過剰反応(暴走)を抑制するが、腸内フローラの劣化に伴い、短鎖脂肪酸の生成量が減少することで、Tレグ細胞に変化する白血球T細胞も減少するため、白血球T細胞の活動が制御不能となって暴走しアレルギーや自己免疫疾患が増える。
5). Degradation of the intestinal flora reduces the amount of short-chain fatty acids that are produced, causing the immune cells (leukocyte T cells) that cause allergies to run away.
That is, immature leukocyte T cells are changed to regulatory leukocyte T cells (T-leg cells) by butyric acid (short chain fatty acid). T-reg cells suppress the activity of mature leukocyte T cells and suppress excessive reaction (runaway) of leukocyte T cells, but as the intestinal flora deteriorates, the production of short chain fatty acids decreases, Since leukocyte T cells that change to T-leg cells also decrease, the activity of leukocyte T cells becomes uncontrollable and runaway, increasing allergies and autoimmune diseases.

 6.漏れる腸になると、腸壁の間隙から、毒素、有害菌が腸管外へ漏れ出す為、腸管外の毒素等に対し白血球等のマクロファージが炎症性サイトカインを分泌するなどして反応し、全身が軽い炎症状態となる。この炎症状態が長く続くことにより白血球等のマクロファージが過敏となり、今まで攻撃にまで至らなかったいわゆる異物を貪食するなどして攻撃し始め、結果として異物の溶解消化が不十分で死んだ白血球等のマクロファージが堆積して動脈硬化の原因となる。 6. When the intestine leaks, toxins and harmful bacteria leak out of the intestinal tract through the gaps in the intestinal wall, so the macrophages such as leukocytes react with the toxins outside the intestinal tract by secreting inflammatory cytokines, and the whole body is light. It becomes inflamed. Due to this prolonged inflammation, macrophages such as leukocytes become hypersensitive and leukocytes that begin to attack by phagocytosing so-called foreign substances that have not been attacked until now, resulting in dead leukocytes that are insufficiently digested and digested by foreign substances The macrophages accumulate and cause arteriosclerosis.

 7.腸内フローラは、神経細胞が刺激信号の伝達において使用される神経伝達物質を生成している。神経伝達物質には、心身の安定、意志及び向上心等を司る「セロトニン」「ドーパミン」等が含まれている。
 腸内フローラが生成した神経伝達物質は、迷走細胞を介して脳を直接的に刺激することから、腸内フローラの劣化に伴い神経伝達物質の生成量が減り、うつ病等の精神疾患の原因となる。
 又、腸内細菌が作る毒素4EPS(4-エチルフェニル硫酸)が漏れる腸等により血中に含まれることで、自閉症を発症、深刻化させる可能性が高くなると考えられる。
 腸内フローラは、その生成物質により脳を支配していると考えられる。
7). Intestinal flora produces neurotransmitters that nerve cells use in transmitting stimulus signals. Neurotransmitters include “serotonin”, “dopamine”, and the like, which are responsible for mind and body stability, will and improvement.
The neurotransmitter produced by the intestinal flora stimulates the brain directly via vagus cells, and as a result, the amount of neurotransmitter produced decreases with the deterioration of the intestinal flora, causing depression and other mental disorders. It becomes.
Moreover, it is thought that the possibility that the autism develops and becomes serious is increased by including the toxin 4EPS (4-ethylphenyl sulfate) produced by intestinal bacteria in the blood by the leaking intestine.
Intestinal flora is thought to dominate the brain by its product.

 8.ヒトの遺伝子が2万3000個と、ミジンコ、マウス等とさほど変わらない量であるのに対し、腸内に常在する腸内フローラは、1200万個の遺伝子を有しており、ヒト生命活動に必要な代謝産物の99%が腸内フローラにより産生されている。 8. The number of human genes is 23,000, which is not much different from Daphnia, mice, etc., whereas the intestinal flora that normally resides in the intestine has 12 million genes, 99% of the necessary metabolites are produced by the intestinal flora.

 9.腸内フローラは、ヒトがつくることができない血液凝固成分であるビタミンKを合成生成する。腸内フローラの劣化は、血液凝固成分の生成量を減少させるため、止血処置が困難になる可能性がある。 9. Intestinal flora synthesizes and produces vitamin K, a blood clotting component that humans cannot make. Deterioration of the intestinal flora reduces the amount of blood clotting components produced, which can make hemostasis difficult.

 10.腸内フローラは、赤血球を形成する葉酸、ビタミンB12を生成し、ヒトの生命活動を担っている。腸内フローラの劣化は、葉酸、ビタミンB12の生成量を減少させて血球形成能を低下させるため、脳貧血、精神疾患を引き起こす可能性がある。
等々が見いだされるに至った。
10. Intestinal flora produces folic acid, vitamin B12, which forms red blood cells, and is responsible for human life activities. Deterioration of the intestinal flora reduces the amount of folic acid and vitamin B12 produced and lowers the ability to form blood cells, which may cause cerebral anemia and mental illness.
And so on.

 また、特開昭61-5022号公報には、腸内細菌叢と生体活動との関係について示され、エンテロコッカスフェカリスの死菌体にエンテロコッカスラクトバチルス、ビフィドバクテリウムといった人に有益な腸内細菌の増殖効果があることが記載されている。特開昭61-5022号公報及びその当時の関連する学術発表により生菌のように取り扱いが煩雑で、医薬品でしか提供ができないそれまでの腸内細菌の取り扱いがより身近なものとなる。 JP-A-61-5022 discloses the relationship between intestinal flora and biological activity, and enterococcus bacteria useful for humans such as Enterococcus faecalis dead cells and Enterococcus lactobacilli, Bifidobacterium. It is described that there is a proliferation effect. JP-A-61-5022 and related scientific publications at that time make handling of intestinal bacteria, which can be provided only with pharmaceuticals, more complicated than live bacteria and more familiar.

 特開平3-151854号公報には、オリゴ糖及び可溶性食物繊維の混合物に、腸内細菌の有害菌Clostridium属、及びEscherichia属を低減させることが示されている。 Japanese Patent Application Laid-Open No. 3-151854 discloses that a mixture of oligosaccharides and soluble dietary fiber can reduce enterobacterium harmful fungi Clostridium genus and Escherichia genus.

 特開2012-111771号公報には、部分加水分解グアーガム(PHGG)を含み、第2の可溶性繊維が、フルクトオリゴ糖(FOS)を含むプレバイオテイクス能を向上させた食品又は医薬品としての食物繊維製剤が開示されている。 JP 2012-111771 A discloses a dietary fiber preparation as a food or pharmaceutical product containing partially hydrolyzed guar gum (PHGG), wherein the second soluble fiber contains fructooligosaccharide (FOS) and has improved prebiotics ability. Is disclosed.

 特表2016-505533号公報には、全粒穀物、豆類、ナッツ、ピーナッツ、コーン(例えば、イエローコーン、ホワイトコーン、レッドコーン、パープルコーン、等の漢方に使用される場合がある食材としての第1の組成物、ゴーヤからなる第2の組成物、及びこれらの発酵物からなる第3の組成物のうち、第1~第3の組成物から選ばれる食材により形成される有益な腸内微生物叢を増進し、日和見病原体を阻害する腸内細菌叢改善組成物が示されている。 JP-T-2016-505533 discloses a grain as an ingredient that may be used in Chinese medicine such as whole grains, beans, nuts, peanuts, corn (eg, yellow corn, white corn, red corn, purple corn, etc.). Beneficial intestinal microorganisms formed by a food material selected from the first to third compositions among the first composition, the second composition made of bitter gourd, and the third composition made of these fermented products Intestinal flora improving compositions that enhance flora and inhibit opportunistic pathogens have been shown.

 特表2011-501940号公報には、粘性化性水溶性繊維、非粘性化性水溶性繊維、及び非水溶性繊維の三元混合物を含有することでビフィズス菌(ビフィドバクテリウム属)の菌数を増大させ、病原菌(大腸菌群、サルモネラ菌など)の菌数を低減させる食品組成物が開示されている。 JP 2011-501940 discloses a bacterium of bifidobacteria (bifidobacterium) by containing a ternary mixture of a viscous water-soluble fiber, a non-viscous water-soluble fiber, and a water-insoluble fiber. Food compositions that increase the number and reduce the number of pathogenic bacteria (such as coliforms and Salmonella) have been disclosed.

 特開2005-154388号公報には、フラクトース分子がβ-2,1結合で環状に結合して構成される環状イヌロオリゴ糖であるシクロフラクタンを有効成分とする腸内機能改善剤が開示されている。 Japanese Patent Application Laid-Open No. 2005-154388 discloses an intestinal function improving agent containing cyclofructan, which is a cyclic inulooligosaccharide composed of fructose molecules cyclically linked by β-2,1 bonds, as an active ingredient. .

 又、特開2007-320946号公報には、エンテロコッカスフェカリス、ラクトバチルスロイテリー及びホエー、根昆布、その他の天然食材粉末との組み合わせにより、有用菌の増殖と有害菌の低減を行うことが記載されている。 Japanese Patent Application Laid-Open No. 2007-320946 describes that enterococcus faecalis, Lactobacillus reuteri and whey, root kelp, and other natural food powders are combined to increase the growth of useful bacteria and reduce harmful bacteria. ing.

 特表2014-513965号公報には、フラクトオリゴ糖、難消化性デキストリン、及びポリデキストロース等の食物繊維組成物により、大腸内での食物繊維の発酵期間を長くして、快適な便通を実現することが開示されている。 Japanese Patent Publication No. 2014-513965 discloses that a dietary fiber composition such as fructooligosaccharide, indigestible dextrin, and polydextrose can be used to lengthen the fermentation period of dietary fiber in the large intestine and realize a comfortable bowel movement. Is disclosed.

 非特許文献2には、ラクトースとイヌリンを20g/日、その後増量し、19日間の摂取を行ったところ腸内細菌環境と便通の改善が示されている。非特許文献3には、イヌリン含有シリアル の摂取により、糞便のpHが低下したことが記載されている。 Non-patent document 2 shows that when lactose and inulin are increased by 20 g / day and then ingested for 19 days, intestinal bacterial environment and bowel movement are improved. Non-patent document 3 describes that the pH of feces was lowered by ingestion of inulin-containing cereal meal.

 特開2016-172761号公報は、非特許文献1と同様に、イヌリン、難消化性デキストリン、ラクチュロース等を含む組成物による便通改善について記載されている。  JP-A-2016-172761 describes improvement of bowel movement with a composition containing inulin, indigestible dextrin, lactulose and the like, as in Non-Patent Document 1.

特開昭61-5022号公報JP-A-61-5022 特開平3-151854号公報Japanese Patent Laid-Open No. 3-151854 特開2012-111771号公報JP 2012-111171 A 特表2016-505533号公報Special table 2016-505533 特表2011-501940号公報Special table 2011-501940 gazette 特開2005-154388号公報JP 2005-154388 A 特開2007-320946号公報JP 2007-320946 A 特表2014-513965号公報Special table 2014-513965 gazette 特開2016-172761号公報JP 2016-172761 A

「腸内フローラ10の真実」、NHKスペシャル取材班著、主婦の友社刊、2015年8月28日“The Truth of Intestinal Flora 10,” NHK Special Coverage, published by Shufu no Tomosha, August 28, 2015 Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons.,Kleessen B1, et.al.,Am J Clin Nutr. 1997 May;65(5):1397-402.Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons., Kleessen B1, et.al., Am J Clin Nutr. 1997 May; 65 (5): 1397-402. Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers.,Brighenti F1, Casiraghi MC, Canzi E, Ferrari A.,Eur J Clin Nutr. 1999 Sep;53(9):726-33.Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers., Brighenti F1, Casiraghi MC, Canzi E, Ferrari A;, Eur Jr.53 9): 726-33.

 上述した様に腸内フローラの科学的解明が進み、上記技術文献、技術的報告等で示すように腸内細菌叢の改善を行う提案や、様々な食物繊維を成分とする健康食品が提案されるに至っているが、腸内フローラの多様性を増加させるような提案は、未だに存在しない。 As described above, scientific elucidation of intestinal flora has progressed, and proposals for improving intestinal flora and health foods composed of various dietary fibers have been proposed as shown in the technical literature and technical reports. However, there are still no proposals to increase the diversity of intestinal flora.

 腸内フローラの「多様性」とは、例えば腸内細菌の種類の多さ、を示す。「増加」とは、例えば腸内細菌の増殖、活性化などを行うことを示し、排便量を増加させたり、腸内フローラの劣化により過去に失われた腸内フローラの機能であって、必要とする又は、必要とする可能性がある機能を再び取り戻すことを含む場合もある。 “Diversity” of intestinal flora indicates, for example, the number of types of intestinal bacteria. “Increase” means, for example, the growth and activation of intestinal bacteria, which is a function of the intestinal flora that has been lost in the past due to the increase in the amount of defecation or deterioration of the intestinal flora. Or may include regaining functionality that may be needed.

 腸内細菌の働きは、未解明な機能を有する細菌も多いが、本発明で示す多様性は、短鎖脂肪酸、エクオール等の有用性のある物質を生成する腸内細菌の種類及びこれらの腸内細菌が形成する腸内フローラの増加を示すことが好ましい場合もある。又、一般に有害菌Clostridium属、及びEscherichia属とされている腸内細菌であっても、ヒトにとって一定の役割を備えた腸内細菌も数多く存在していることから、有害菌、有用菌、日和見菌が共存した状態でその増加を腸内細菌の多様性と示す場合もある。 Although the function of intestinal bacteria has many unexplained functions, the diversity shown in the present invention is the type of intestinal bacteria that produce useful substances such as short-chain fatty acids and equol, and their intestines. It may be preferable to show an increase in the intestinal flora formed by the internal bacteria. In addition, there are many enterobacteria that have a certain role for humans, even in the case of enterobacteria that are generally classified as genus Clostridium and Escherichia. In some cases, the increase in the presence of bacteria can be shown as the diversity of enteric bacteria.

 その他、腸内フローラの多様性は、有益な腸内細菌の種類の多さを示す場合や、有害菌、有用菌及び日和見菌のバランスがとれた状態を示す場合もある。 In addition, the diversity of intestinal flora may indicate a variety of beneficial intestinal bacteria, or a balanced state of harmful bacteria, useful bacteria, and opportunistic bacteria.

 本発明は、上記に鑑みてなされたもので、今般解明が進む腸内細菌と、ヒトとの関係について鋭意研究した結果、
 ヒトが腸内フローラを生かしている、という人間中心の所謂「天動説」ではなく、腸内フローラが人間を生かしている、即ち、腸内フローラの健康を作り出して初めてヒトの健康が守られるという腸内フローラが中心の所謂「地動説」に基づくべきであるとの知見に至り本発明に到達した。
The present invention has been made in view of the above, and as a result of earnest research on the relationship between enterobacteria, which are now elucidated, and humans,
It is not the so-called “natural movement theory” that humans make use of intestinal flora, but intestinal flora makes use of humans, that is, the intestines that human health is protected only after the health of intestinal flora is created. The inventor has arrived at the present invention by finding that the inner flora should be based on the so-called “ground motion theory”.

 本発明は、腸内細菌が食べる物を主成分としながら、ヒトが安定的に又は、抵抗なく食することができる食物繊維状物及び/又は腸内細菌熱水抽出物よりなる可食性組成物(食品)を提供することを実現する。 The present invention relates to an edible composition comprising a dietary fiber and / or an enterobacterial hot water extract that can be eaten stably or without resistance by human beings, which are mainly eatable by intestinal bacteria. Realize the provision of (food).

 腸内細菌、及び腸内フローラが食べる物としては、食物繊維状物が例示される。
 本発明で示す腸内フローラは、腸内細菌の集まりであるが、その機能性を説明する場合は、腸内細菌単体の機能性を示す。
Examples of the foods eaten by the intestinal bacteria and the intestinal flora include dietary fiber.
The intestinal flora shown in the present invention is a collection of intestinal bacteria, but when explaining its functionality, it shows the functionality of the intestinal bacteria alone.

 食物繊維状物としては、食物繊維単体又は、食物繊維を含む天然又は合成の食材が例示される。食材は、天然又は天然由来のものが、腸内細菌及び腸内フローラが多様性を増加させ、有効な生成物を多く生成する点で好ましい。 Examples of the dietary fiber include dietary fiber alone or natural or synthetic foods containing dietary fiber. Ingredients are preferably natural or naturally derived in that enteric bacteria and intestinal flora increase diversity and produce many effective products.

 食物繊維には、水溶性食物繊維、非水溶性食物繊維の何れもが含まれる。
 又、本発明で示す食物繊維には、合成食物繊維、天然由来の食物繊維の何れか一方又は両方が含まれるが、合成された食物繊維は、天然由来の食物繊維が備える機能、成分が欠けていたり、体内での消化吸収が十分でないものがあり、腸内細菌及び腸内フローラにとって、好ましい食べ物(資化物)ではない場合があることから、天然由来の食物繊維が好ましい場合がある。
Dietary fiber includes both water-soluble dietary fiber and water-insoluble dietary fiber.
In addition, the dietary fiber shown in the present invention includes either or both of synthetic dietary fiber and naturally-occurring dietary fiber, but the synthesized dietary fiber lacks the functions and components of the naturally-derived dietary fiber. In some cases, digestive absorption in the body is not sufficient, and natural dietary fiber may be preferred because it may not be a preferred food (assistant) for intestinal bacteria and intestinal flora.

 本発明における食物繊維について、より具体的には、例えば腸内細菌が腸管で発酵吸収する組成物、即ち腸内細菌の食べ物(資化する物)であって、腸内細菌が、短鎖脂肪酸を生成する為の成分を可食性組成物とすることで、腸内細菌の多様性を増加させることができる。 More specifically, the dietary fiber in the present invention is, for example, a composition in which enterobacteria are fermented and absorbed in the intestinal tract, that is, an enterobacterial food (utilized product), wherein the intestinal bacteria are short-chain fatty acids. By using an edible composition as a component for producing, the diversity of enteric bacteria can be increased.

 短鎖脂肪酸を生成する食べ物としては、例えば天然由来のイヌリンが例示されるが、チコリ、菊芋、ごぼう、にら等から精製抽出されたものや、チコリ根、菊芋、ごぼう、にらの原材料成分からイヌリンを所定量(例えば70%以上)含有する天然抽出物が、本来の天然由来の食物繊維能を十分に備えており、より安価に入手できる点でより好ましい。 Examples of foods that produce short-chain fatty acids include naturally derived inulin, but those purified and extracted from chicory, chrysanthemum, burdock, leek, etc., and raw material components of chicory root, chrysanthemum, burdock, and leek Therefore, a natural extract containing a predetermined amount (for example, 70% or more) of inulin is more preferable in that it has sufficient natural dietary fiber capacity and can be obtained at a lower cost.

 尚、短鎖脂肪酸を生成する食べ物だけでは、ヒトが安定的に食することが困難な場合は、更に味覚、食感を整える果汁、蜂蜜、果実由来の食物繊維を含有することが好ましい。
 この場合の、果実に係る食物繊維についても、天然の食物繊維と同様に腸内フローラの多様性を増加させることができ、全体として、腸内フローラに適した資化組成物とすることができる。
In addition, when it is difficult for humans to eat stably only with foods that produce short-chain fatty acids, it is preferable to further contain fruit juice, honey, and fruit-derived dietary fibers that adjust the taste and texture.
In this case, the dietary fiber related to the fruit can also increase the diversity of the intestinal flora in the same manner as the natural dietary fiber, and as a whole can be an assimilated composition suitable for the intestinal flora. .

 「安定的」とは、毎日、一定間隔等で食することの他、単発であっても、食することができ、再び食することが可能であると思える程度も含まれる。
 尚、食品添加物等、腸内細菌の劣化因子はなるべく用いないことが好ましいことから、苦みやその他の食材自体の独特な食感、味覚がある場合、より均一な成分の混和、造粒をすることで、ヒトにとっても安定的に食することが可能となる。
“Stable” includes not only eating at regular intervals every day, but also to the extent that it is possible to eat even if it is a single shot, and to eat again.
In addition, since it is preferable not to use as much as possible degradation factors of enteric bacteria such as food additives, if there is a bitter taste or a unique texture or taste of other ingredients themselves, more uniform mixing of ingredients and granulation This makes it possible for humans to eat stably.

 腸内細菌が産生する短鎖脂肪酸は、上述の通り、脂肪細胞の肥大化を阻止して肥満を解消することから、肥満によって生じる肝臓ガン、乳ガン、食道ガンなどの予防や、制御性T細胞の産生能を高めて、アレルギーの原因となる白血球T細胞の暴走を抑制したり、腸のバリア機能を向上させ、漏れる腸を防止する。 As described above, short-chain fatty acids produced by intestinal bacteria prevent fat cell hypertrophy and eliminate obesity, and thus prevent liver cancer, breast cancer, esophageal cancer, etc. caused by obesity, and regulatory T cells. To increase the production ability of the leukocytes, suppress the runaway of white blood cell T cells that cause allergies, improve the barrier function of the intestines, and prevent leaking intestines.

 「漏れる腸」は、上述の通り、腸内細菌の劣化に伴い、腸内細菌の短鎖脂肪酸産生能が低下することで、腸のバリア機能が低下して腸管に隙間ができることで、この隙間から、血中等へ有害な細菌や毒素が漏れ出すことを意味する。漏れ出した血中の毒素や細菌に対し、白血球、マクロファージが攻撃を行う為、全身が軽い炎症状態となり、インスリンの活性を阻害したり、腸の細胞を刺激することで分泌されるインクレチンが減少し、インスリンの分泌量が減って糖尿病の原因となると共に貪食による攻撃の結果、白血球等の死骸が血管内に堆積して、動脈硬化の原因となる。 As described above, the “leaking intestine” is a decrease in the ability of the intestinal bacterium to produce short-chain fatty acids due to the deterioration of the intestinal bacterium, thereby reducing the intestinal barrier function and creating a gap in the intestinal tract. This means that harmful bacteria and toxins leak into the blood. Because leukocytes and macrophages attack the leaked toxins and bacteria in the blood, the whole body becomes mildly inflamed, inhibiting insulin activity and stimulating intestinal cells. As a result of the attack by phagocytosis, dead bodies such as leukocytes accumulate in the blood vessels and cause arteriosclerosis.

 又、肥満は、腸内細菌の一つであるガンを誘発させる可能性が高いアリアケ菌を増加させる。
 そこで、本発明は、腸内細菌を健康にし、多様性を増加させることで、短鎖脂肪酸の産生を促進させるような、腸内細菌の食べ物を含む可食性組成物を提供することを実現した。
Obesity also increases Ariake bacteria, which is likely to induce cancer, one of the enteric bacteria.
Therefore, the present invention has realized providing an edible composition containing foods of enteric bacteria that promotes the production of short-chain fatty acids by making enteric bacteria healthy and increasing diversity. .

 短鎖脂肪酸は、酢酸、プロピオン酸、酪酸、これらのエステル、これらの塩からなり、主に腸内フローラによって生成されるが、本発明は、腸内フローラにおける短鎖脂肪酸の生成量を補う目的で短鎖脂肪酸を別途添加する場合もある。 Short chain fatty acids are composed of acetic acid, propionic acid, butyric acid, their esters, and their salts, and are mainly produced by intestinal flora. The present invention is intended to compensate for the production of short chain fatty acids in intestinal flora. In some cases, short-chain fatty acids may be added separately.

 短鎖脂肪酸を産生する腸内細菌の食べ物(資化組成物)としては、例えば上述のようにイヌリンが示され、天然のイヌリンを含む素材としては、チコリ、菊芋、ごぼう、にら等が示される。
 特にチコリ根の抽出物が、天然由来のイヌリンを多く含むものであって、合成されたイヌリンに比べ、吸収性、機能性が優れている点で好ましい。一般に合成した食物繊維は、吸着能が、天然のものと比べて、強い場合があり、ヒトに必要なミネラルを体外へ排出してしまうなどのリスクがあることから天然由来のイヌリンを用いることが好ましい場合もある。
Examples of enterobacterial foods that produce short-chain fatty acids (assimilation compositions) include inulin as described above, and examples of natural inulin-containing materials include chicory, chrysanthemum, burdock, and leek. It is.
The extract of chicory root is particularly preferable in that it contains a large amount of inulin derived from nature, and is superior in absorbability and functionality compared to synthesized inulin. Synthetic dietary fibers generally have stronger adsorption capacity than natural ones, and use natural inulin because there is a risk that minerals necessary for humans may be discharged outside the body. It may be preferable.

 更に本発明は、腸内フローラの賦活を行うための主に腸内細菌が食する物質を、ヒトが、安定的に摂取可能とする形態で提供することで、腸内フローラの多様性の増加を実現する。 Furthermore, the present invention provides an increase in the diversity of intestinal flora by providing a substance that can be ingested stably by humans, which is a substance that is mainly consumed by enterobacteria to activate intestinal flora. Is realized.

 本発明は、腸内フローラの多様性を増加させるために、全重量に対し、チコリ根粉末及び菊芋粉末を、全重量に対し25~70%(好ましくは、40%~50%)、果実成分(実施例1,2)を10~50%(好ましくは、25%~40%)、燕麦、造粘剤であって且つ食物繊維であるグアーガム、及び腸内細菌死菌末を含むことが例示される。
 造粘剤として使用しているグアーガムは、更に食物繊維として機能するその他の天然ガム等を用いることが好ましい。
 チコリ根抽出物は、水溶性食物繊維であるイヌリンが多く含まれ、糞便の排出効率の増加に適当である。
In order to increase the diversity of intestinal flora, the present invention comprises 25 to 70% (preferably 40% to 50%) of chicory root powder and chrysanthemum powder with respect to the total weight, fruit components Examples (Examples 1 and 2) include 10-50% (preferably 25% -40%), buckwheat, guar gum which is a thickener and dietary fiber, and enterobacterial bacterial powder. Is done.
As the guar gum used as a thickener, it is preferable to use other natural gums that function as dietary fibers.
The chicory root extract is rich in inulin, which is a water-soluble dietary fiber, and is suitable for increasing fecal excretion efficiency.

 チコリは、ハーブ系の野菜であり、その抽出の程度によっては、ラクチュピリン等の苦み成分や風味、香りに特徴があることから、腸内細菌にとっては、好ましいとしても、ヒトが安定的に摂取する為には、緩和する等の工夫が必要となるが、本発明は、これらを粉末化した後、果実粉末を加え、均一的な混和と、造粒を行う手法により、苦み等の天然由来の独自の味覚を和らげてヒトが安定的に食することが可能な組成物を提供することができる。均一的に混和する手段としては、流動層造粒手法が好ましく、造粒成分の均一性が良好でしかも苦みがなくまろやかで安定的に食することが可能な粉末食品が形成できる。 Chicory is a herb-based vegetable and, depending on the degree of extraction, has characteristics of bitter ingredients such as lactupirin, flavor, and fragrance. In order to achieve this, it is necessary to devise measures such as mitigating, but the present invention, after powdering these, add fruit powder, and by mixing uniformly and granulating, the natural origin such as bitterness It is possible to provide a composition that can relax a unique taste and can be stably eaten by humans. As a means for uniformly mixing, a fluidized bed granulation method is preferable, and a powdered food that has good uniformity of granulation components and is bitter and can be eaten mellowly and stably can be formed.

 イヌリンには、砂糖を原材料に用いた酵素合成法による合成イヌリンや、チコリ、菊芋等から抽出した天然由来のイヌリンが存在するが、合成イヌリンは、安価で、純度が高い反面、その製造工程の特性から天然由来のものからすると食物繊維としての成分が不足し、胃腸内での消化吸収が悪いとされていることから腸内細菌に資化され難い面があると考えられる。これに対し天然由来のイヌリンは、天候、収穫量に影響を受けたり、品質が安定しない場合があるが、イヌリン本来の成分が維持でき、しかも体内での吸収が良いことから、腸内細菌による資化に優れているものと考えられる。 Inulin includes synthetic inulin obtained by enzymatic synthesis using sugar as a raw material, as well as naturally-derived inulin extracted from chicory, chrysanthemum, etc., but synthetic inulin is inexpensive and highly pure. From the nature, it is thought that there is a problem that it is difficult to be assimilated by intestinal bacteria because it is considered that the components derived from nature are insufficient and the digestive absorption in the gastrointestinal tract is poor. In contrast, naturally-occurring inulin may be affected by the weather and yield, and the quality may not be stable, but it can maintain the original components of inulin and is well absorbed by the body. It is thought that it is excellent in utilization.

 しかしながら天然イヌリンの中でも、菊芋由来のイヌリンは、菊芋自体にイヌリンを分解する成分が含まれているため、長期間の保存に向いていないことから、腸内細菌に資化され、その多様性を増加させる成分として、チコリ根抽出物が好適である。天然素材を利用し、サプリメント的な食材形態を形成するには、天然素材がもつ、味覚、臭覚を制御する必要がある。この制御は、おおよそ添加物によって、抑えることができるが、食品用の添加物の中には、腸内細菌に対しダメージを与える場合があり、逆の効果となることもあることからなるべく添加物の使用を抑えることが好ましい。 However, among the natural inulins, the inulin derived from chrysanthemums is not suitable for long-term storage because it contains components that degrade inulin in the chrysanthemum salmon itself. A chicory root extract is preferred as the component to be increased. In order to form supplemental food forms using natural materials, it is necessary to control the taste and smell of natural materials. This control can be suppressed by some additives, but some food additives may damage intestinal bacteria and may have the opposite effect. It is preferable to suppress the use of.

 そこで、均一成分、均一粒径となる造粒手段を用いることで、いわゆる天然由来の味、臭い等を抑えることができ、ヒトであっても安定的に食することができる食品が製造可能となるのである。 Therefore, by using granulation means with uniform ingredients and a uniform particle size, so-called naturally-derived taste, odor, etc. can be suppressed, and foods that can be eaten stably even by humans can be manufactured. It becomes.

 尚、短鎖脂肪酸の生成能を向上させる天然由来の食物繊維の他、β-グルカン、フルクタン、アルビノキシラン、コンニャクグルコマンナン、ヘミセルロース(大豆多糖類、米ぬか、玄米 トウモロコシ外皮),ポリデキストロース、リグニン、ハイメトキシペクチン、オリゴ糖:ラフィノース、スタキオース(ガラクトオリゴ糖)フラクトオリゴ糖、マルトトリオース、マルトテトラオース、マルトペンタオース、フコイダン(めかぶ、昆布、モスク等の海草類)、水溶性大豆多糖類、プルラン、等の食物繊維が、腸内フローラの多様化を増加させることから、ヒトが安定的に食する可食性組成物に含まれても良い。 In addition to natural dietary fiber that improves the ability to produce short chain fatty acids, β-glucan, fructan, albinoxylan, konjac glucomannan, hemicellulose (soy polysaccharides, rice bran, brown rice, corn hulls), polydextrose, lignin, High methoxy pectin, oligosaccharide: raffinose, stachyose (galacto-oligosaccharide) fructooligosaccharide, maltotriose, maltotetraose, maltopentaose, fucoidan (seaweed such as mekabu, kelp, mosque), water-soluble soybean polysaccharide, pullulan, etc. The dietary fiber may increase the diversification of intestinal flora, so it may be included in an edible composition that humans eat stably.

 本発明は、腸内細菌に有効な食物であって、ヒトが安定的に食することができる好ましくは天然由来の食物繊維状物及びエンテロコッカスフェカリスAD101(FERM P-20739)、ラクトバチルスロイテリAD302(FERM P-20741)、及びラクトバチルスアシドフィルスAD206の熱水抽出物(死菌体)を含む可食性組成物により、腸内フローラの多様性を増加させることで、ヒトの健康を実現する。 The present invention is a food effective for enterobacteria, preferably a naturally occurring dietary fiber that can be stably eaten by humans, Enterococcus faecalis AD101 (FERM P-20739), Lactobacillus reuteri AD302 ( FERM P-20741) and an edible composition containing a hot water extract (dead cells) of Lactobacillus acidophilus AD206 increases the diversity of intestinal flora, thereby realizing human health.

 腸内フローラが食し、腸内フローラを健康にして(活性を高めて)多様性を回復的に増加させる成分であって、当該成分をヒトが安定的に摂取可能な構成であればよく、更には、腸内細菌の食べ物であって、ヒトに有益な短鎖脂肪酸を生成するものが好ましい。 It is a component that eats the intestinal flora, makes the intestinal flora healthy (increases its activity), and reversibly increases diversity, as long as the component can be stably ingested by humans. Are preferably enteric bacterial foods that produce short-chain fatty acids that are beneficial to humans.

 本実施形態では、チコリ、チコリ根抽出物、菊芋等の食物繊維成分を腸内細菌が好んで食する自然の食物繊維とヒトが安定的に食することができる程度の味覚を備えた果実等の食物繊維の両方を組み合わせた可食性組成物とすることが好ましい。 In this embodiment, natural dietary fiber that enteric bacteria prefer to eat dietary fiber components such as chicory, chicory root extract, chrysanthemum, etc., fruit with a taste that can be eaten stably by humans, etc. It is preferable that the edible composition is a combination of both dietary fibers.

 本発明におけるチコリ、チコリ根抽出物又は菊芋は、イヌリンを多く含み、腸内細菌により食され、短鎖脂肪酸に分解される。菊芋は、イヌリンを分解する成分が含まれるため、有効量のイヌリンを確保することは、精製抽出を行う必要があり、天然性を欠く場合もあることから、チコリ根抽出物が、腸内細菌の食べ物として好適である。 The chicory, chicory root extract or chrysanthemum pod in the present invention contains a lot of inulin, is eaten by intestinal bacteria, and is decomposed into short chain fatty acids. Since chrysanthemums contain ingredients that degrade inulin, securing an effective amount of inulin requires purified extraction and may lack naturalness. Suitable as food.

 イヌリンは、水と接触することで、膨潤したゲル状物となる過程で、糖を取り込むことから、体内では、糖の吸収を抑えることができる。
 従って、イヌリンの量を実施例で示す様に4g以上と多くすることで、食品としての味覚の幅を広くすることができ、ヒトが摂取しやすく、毎日の摂取を可能とすることができる。
Inulin can absorb sugar in the body because it takes in sugar in the process of becoming a swollen gel when it contacts water.
Therefore, by increasing the amount of inulin to 4 g or more as shown in the examples, the range of taste as a food can be widened, and it is easy for humans to take and can be taken daily.

 尚、本発明の実施形態としてイヌリン含有の天然食材を主成分として示したが、その他、大麦、燕麦、グアーガム、その他の増粘多糖類、グルコマンナン、ペクチン、ヘミセルロース、リグニン、アルギン酸、ポリデキストロース、難消化性デキストリン、難消化性澱粉、フコイダン(めかぶ)、水溶性大豆多糖類、プルラン及びこれらの分解物等の水溶性食物繊維を含む天然食材及びその抽出物を用いても良く、更にヒトが安定して食することができる味覚、風味、食感を実現するための風味調整用食物繊維材料を組み合わせて造粒物を形成しても良い。 In addition, although an inulin-containing natural food ingredient has been shown as a main component as an embodiment of the present invention, barley, buckwheat, guar gum, other thickening polysaccharides, glucomannan, pectin, hemicellulose, lignin, alginic acid, polydextrose, Natural foods and extracts thereof containing water-soluble dietary fiber such as indigestible dextrin, resistant starch, fucoidan, water-soluble soybean polysaccharide, pullulan and their degradation products may be used. A granulated product may be formed by combining flavor-adjusting dietary fiber materials for realizing a taste, flavor, and texture that can be eaten stably.

 風味調整用は、必ずしも風味を調整するだけでなく、腸内フローラの多様性の増加を実現するものが好ましく、又、腸内フローラの多様性を増加させる上述した食物繊維を含有する天然食材単体を、造粒粉末加工した可食性組成物であっても、ヒトが安定して食することができるものであれば、良い場合もあり、好適な場合もある。 For flavor adjustment, it is preferable not only to adjust the flavor, but also to increase the diversity of intestinal flora, and the natural food alone containing the above-mentioned dietary fiber that increases the diversity of intestinal flora Even if it is an edible composition obtained by processing granulated powder, it may be good or may be suitable if it can be eaten stably by humans.

 本発明における腸内細菌熱水抽出物は、エンテロコッカスフェカリスAD101(FERM P-20739)、ラクトバチルスロイテリAD302(FERM P-20741)、及びラクトバチルスアシドフィルスAD206の熱水抽出物(死菌体)を示す。これらは、例えば、特開昭61-5022号公報、特開2007-320946号公報に記載されているように、有用菌の増殖能が示されており、天然の食物繊維との組み合わせにおいて、腸内細菌の多様性を更に増加させることを可能とする。
 熱水抽出手法としては、特開昭61-5022号公報等に示される手法が例示される。
The intestinal bacterial hot water extract in the present invention represents a hot water extract (dead cell) of Enterococcus faecalis AD101 (FERM P-20739), Lactobacillus reuteri AD302 (FERM P-20741), and Lactobacillus acidophilus AD206. . As described in, for example, JP-A-61-5022 and JP-A-2007-320946, they exhibit the ability to grow useful bacteria, and in combination with natural dietary fiber, It is possible to further increase the diversity of internal bacteria.
Examples of the hot water extraction method include the method shown in JP-A-61-5022.

 食品の形態としては、均一な粒径で、しかも均一な成分の混和ができる流動層造粒手法を用いた粉末を、更に顆粒としたり、カプセル状、糖衣状、水溶液状、にしてもよい。
 更にふりかけ、清涼飲料、ビスケット、せんべい等に加工してもよい。
As a form of the food, a powder using a fluidized bed granulation method with a uniform particle size and capable of mixing the uniform components may be further granulated, made into a capsule shape, a sugar coating shape, or an aqueous solution shape.
Further, it may be processed into sprinkles, soft drinks, biscuits, rice crackers and the like.

 尚、エンテロコッカスフェカリスAD101(FERM P-20739)、及びラクトバチルスロイテリAD302(FERM P-20741)は、特許生物寄託センターにそれぞれの寄託番号に基づいて寄託されている。 Enterococcus faecalis AD101 (FERM P-20739) and Lactobacillus reuteri AD302 (FERM P-20741) are deposited at the Patent Biological Depositary Center based on their respective deposit numbers.

 引き続いて、本発明をその実施例を参照して説明する。なお、本発明は、これらの実施例によって限定されるものでない。 Subsequently, the present invention will be described with reference to the examples. In addition, this invention is not limited by these Examples.

実施例1及び2
 表1に示す組成で実施例1及び2を実施した。
Examples 1 and 2
Examples 1 and 2 were carried out with the compositions shown in Table 1.

 表1で示す実施例1は、チコリ根抽出物(イヌリン90%)を全重量%に対して20%、菊芋5.2%、オーツ麦(燕麦)6%、グアーガム3%、リンゴ、マンゴー、バナナ等の食物繊維を含む果実成分32%等からなる粉末を、流動層造粒手法で均一な粉末化を行うことで、チコリ固有の苦みを取り除き、腸内細菌が食する食物であって、ヒトが安定的に食することができる可食性組成物を製造する。 Example 1 shown in Table 1 shows that chicory root extract (90% inulin) is 20% based on the total weight%, chrysanthemum pod 5.2%, oat 6%, guar gum 3%, apple, mango, A powder consisting of 32% fruit components containing dietary fiber such as banana, etc., is a food that is eaten by intestinal bacteria by removing the bitterness inherent in chicory by uniform powdering by fluidized bed granulation technique, An edible composition that can be stably eaten by humans is produced.

 流動層造流装置を用いてバインダーに食物繊維でもあるグアーガム(全重量に対して3%)を用いて、これをスプレー噴射させながら、造粒室内の原材料粉末の下側から、熱風を吹き付けて、場合によっては、回転板上で粒子を流動化させながら造粒し、粒径及び成分が均一な粉末又は顆粒を形成する。 Using guar gum (3% of the total weight) that is also a dietary fiber as a binder using a fluidized bed flow generator, spraying hot air from the lower side of the raw material powder in the granulation chamber while spraying it. In some cases, the particles are granulated while fluidizing them on a rotating plate to form powders or granules having uniform particle diameters and components.

 この造粒手法は、チコリ根抽出物、果実成分等を均一に混和して更に均一の粒径をもつ粉末又は顆粒を製造することから、チコリ根特有の味覚等を緩和して、ヒトでも食しやすい可食性組成物を形成する。 This granulation method uniformly mixes chicory root extract, fruit components, etc. to produce powders or granules having a more uniform particle size. Therefore, the taste unique to chicory root is alleviated and eaten by humans. Form edible edible compositions.

 1回に表1の実施例で示す成分を含む可食性組成物粉末10g、1日1回~5回、好ましくは3回を目安に摂取する。これを継続することで、排便量が増え、腸内フローラの多様性を回復的に増加させ、腸内細菌の健康と共にヒトの健康を実現する。 Ingestion of edible composition powder 10 g containing the ingredients shown in the examples of Table 1 at a time, once to 5 times a day, preferably 3 times a day By continuing this, the amount of defecation increases, the diversity of intestinal flora is recovered, and human health is achieved along with the health of intestinal bacteria.

 本実施例では、イヌリンとして、チコリ根抽出物を用いたが、菊芋抽出物、その他ゴボウ、にらから抽出したものであっても良い場合もあるが、腸内細菌の資化に好ましく、しかも多様性を増加させて、排便量を増やす為に合成の食品添加物を極力使用せず、摂取量をある程度多くする(1日10g~30g)こと、継続的使用の為に製品の安定性が維持できることが好ましいことから、チコリ根抽出物が、イヌリン含有量が多く、しかも腸内細菌及び腸内フローラにとって好ましい。 In this example, chicory root extract was used as inulin, but it may be extracted from chrysanthemum extract, other burdock, and leek, but is preferable for assimilation of intestinal bacteria, To increase diversity, increase the amount of defecation as much as possible without using synthetic food additives as much as possible (10g-30g a day), and the stability of the product for continuous use Because it is preferably maintainable, chicory root extract is preferred for intestinal bacteria and intestinal flora with high inulin content.

 尚、チコリは、苦み成分を持つことから、微細粉末化した後、流動層造粒手法でその他の果実等の甘みをもつ食物繊維成分と均一に混和することで、苦みがまろやかになり、食品添加物を抑えながら腸内細菌の資化に資することができると共にヒトも継続的に接収可能となる健康食品となる。 Since chicory has a bitter component, it can be finely pulverized and then mixed uniformly with dietary fiber components with sweetness such as other fruits using a fluidized bed granulation method. It becomes a health food that can contribute to the assimilation of intestinal bacteria while suppressing additives, and that can be continuously received by humans.

 表1の実施例2は、実施例1に比べ、チコリ根抽出物がおおよそ2倍の量となっている。
 これら粉末を医薬品の製造に用いられる流動層造粒手法を用いて、成分が均一な状態を形成して、腸内細菌の食べ物を苦み等を抑えてヒトが継続的に食するに適当な味覚の安定化を得ることが可能となる。
Example 2 in Table 1 has approximately twice the amount of chicory root extract compared to Example 1.
Using the fluidized bed granulation technique used for the manufacture of pharmaceuticals, these powders form a uniform state and are suitable for humans to continuously eat foods of intestinal bacteria while suppressing bitterness. Can be obtained.

 これらの成分を粉末化して調整された粉末又は顆粒の食品10g(実施例1)を一回の摂取量とし、そのまま食するか、牛乳、水等に溶かして飲む形で、1日3回から5回程度摂取する。相当量のイヌリン等の食物繊維をヒトが食することから、腸内に届いたこれら天然由来のイヌリン含有食材等を腸内細菌叢が食することで短鎖脂肪酸を生成すると共に排便量を増加させ腸内フローラの活性が向上させることで短鎖脂肪酸の効果が発揮されるが、実施例1で示す成分を、均一な粒径と成分となる粉末、顆粒末状にした食品についての官能試験(被験者10名)の結果では、多少甘みがあるものの、チコリ固有の苦み、風味が抑えられていて、まろやかな食感を備えているとの回答が8名と多く、継続的に又は、食することに抵抗が無い食品として評価するものも半数以上であった。又、便通の改善、及び回数についても、7名から8名のヒトが排便回数が増加したとの回答が得られた。 10 g of powdered or granulated food prepared by pulverizing these ingredients (Example 1) is taken as a single intake, eaten as it is, or dissolved in milk, water, etc. Ingest about 5 times. Since humans eat a considerable amount of dietary fiber such as inulin, the intestinal microflora eats these naturally-derived inulin-containing foods that reach the intestines, generating short-chain fatty acids and increasing the amount of defecation The effect of short-chain fatty acids is demonstrated by improving the activity of the intestinal flora, but the sensory test on the ingredients shown in Example 1 having a uniform particle size and powder as a component, and a granular powder food According to the results of (10 test subjects), although there are some sweetnesses, there are many respondents with 8 people that the bitterness and flavor peculiar to chicory are suppressed and that they have a mellow texture. More than half of the products were evaluated as foods without resistance. As for the improvement and frequency of bowel movements, 7 to 8 people answered that the number of bowel movements increased.

Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001

実施例3及び4
 下記の組成で実施例3及び4を実施した。
Examples 3 and 4
Examples 3 and 4 were carried out with the following composition.

[実施例3の組成]
大麦(胚乳)                              20%
グアーガム                                3%
果汁成分粉末(食物繊維)                        60%
エンテロコッカスフェカリスAD101(寄託番号P-20739)   2.82%
ラクトバチルスロイテリAD302(寄託番号P-20741)      0.2%
ラクトバチルスアシドフィルスAD206                0.1%
その他(はちみつ粉末等)                     13.88%
                                合計 100%
[Composition of Example 3]
Barley (endosperm) 20%
Guar gum 3%
Fruit juice ingredient powder (dietary fiber) 60%
Enterococcus faecalis AD101 (deposit number P-20739) 2.82%
Lactobacillus reuteri AD302 (deposit number P-20741) 0.2%
Lactobacillus acidophilus AD206 0.1%
Others (honey powder, etc.) 13.88%
Total 100%

[実施例4の組成]
大豆胚軸抽出物(エキス)粉末                      10%
グアーガム                                3%
果汁成分粉末(食物繊維)                        70%
エンテロコッカスフェカリスAD101(寄託番号P-20739)   2.82%
ラクトバチルスロイテリAD302(寄託番号P-20741)      0.2%
ラクトバチルスアシドフィルスAD206                0.1%
その他(はちみつ粉末等)                     13.88%
                                合計 100%
[Composition of Example 4]
Soybean hypocotyl extract (extract) powder 10%
Guar gum 3%
Fruit juice component powder (dietary fiber) 70%
Enterococcus faecalis AD101 (deposit number P-20739) 2.82%
Lactobacillus reuteri AD302 (deposit number P-20741) 0.2%
Lactobacillus acidophilus AD206 0.1%
Others (honey powder, etc.) 13.88%
Total 100%

 実施例3は、食物繊維として大麦を用いたものであり、果汁繊維、その他の成分は、実施例1及び2と同様、バナナ、リンゴ、マンゴー等の果実繊維、その他として、蜂蜜等が示される。 Example 3 uses barley as dietary fiber, and fruit juice fiber and other components are fruit fibers such as banana, apple and mango, and honey and the like are shown as in Examples 1 and 2. .

 エンテロコッカスフェカリスAD101(寄託番号P-20739)、ラクトバチルスロイテリAD302(寄託番号P-20741)、及びラクトバチルスアシドフィルスAD206の熱水抽出物(死菌体)は、上述の通り有用常在菌の増殖能を備えていることから、腸内に常在する腸内細菌の多様性をより高める機能を有する。 Enterococcus faecalis AD101 (deposit number P-20739), Lactobacillus reuteri AD302 (deposit number P-20741), and hot water extract (dead cells) of Lactobacillus acidophilus AD206, as described above, have the ability to grow useful resident bacteria. Therefore, it has a function to further increase the diversity of intestinal bacteria resident in the intestine.

 1回の摂取量としては、10g~30g/1包を1日3回摂取することが好ましいが、体質等を考慮して摂取することが好ましい。 As a single intake, it is preferable to take 10 g to 30 g / pack three times a day, but it is preferable to take in consideration of the constitution.

 大麦(胚乳部分)は、水溶性食物繊維βーグルカンを多く含み、イヌリンと同様に、腸内細菌の多様性を増加させる機能を有し、糞便量を増加させる。 Barley (endosperm portion) contains a large amount of water-soluble dietary fiber β-glucan and, like inulin, has the function of increasing the diversity of intestinal bacteria and increases the amount of feces.

 大麦(胚乳)粉末は、大麦胚乳部分を分離したものが好ましく、大麦粉を温水抽出、固形分離して得られた抽出物粉末、又は、気流分級又は篩にかけて分離抽出する。
 また、大麦の他、実施例1及び2と同様に、燕麦(オーツ麦)を用いてもよい。
The barley (endosperm) powder is preferably obtained by separating the barley endosperm portion. The barley flour is extracted by hot water extraction and solid separation, or air separation or sieving.
In addition to barley, buckwheat (oat) may be used as in Examples 1 and 2.

 製法としては、大麦粉末、果汁成分粉末等をグアーガムを用いて流動層造粒手法を用いて、均一な成分及び粒径をもつ粉末又は顆粒にする。 As a manufacturing method, barley powder, fruit juice component powder, etc. are made into powder or granules having a uniform component and particle size by using a fluidized bed granulation technique using guar gum.

 以上の実施例は、粉末状、又は顆粒状に形成したものを示したが、更に、錠剤状、棒状、板状、ブロック状、固形状、丸状、液状、飴状、ペースト状、クリーム状、ハードカプセルやソフトカプセルのようなカプセル状、カプレット状、タブレット状、ゲル状、ゼリー状、その他の食品形態で製造しても良いが、少なくとも、粉末状にした後、これらの形態に変更することが好ましい。 The above examples showed powders or granules formed, but in addition, tablets, rods, plates, blocks, solids, rounds, liquids, bowls, pastes, creams , Capsules like hard capsules and soft capsules, caplets, tablets, gels, jellies, and other food forms may be produced, but at least they can be changed to these forms after being powdered preferable.

 本実施例の様に、天然由来性が大きい大麦(胚乳)抽出物粉末を多く含むことで、生じる大麦本来の雑味を和らげ、ヒトも安定的、継続的に食することが可能となる。 As in this example, by containing a lot of barley (endosperm) extract powder having a high natural origin, it is possible to relieve the original miscellaneous taste of the barley and to allow humans to eat stably and continuously.

 実施例4は、腸内でエクオールを産出する原料となるイソフラボンを多く含む大豆胚軸抽出物粉末を10%~50%程度含有する。大豆胚軸抽出物には、苦み、えぐみ等があることから、これを緩和し、味覚、食感を整えるため、食品添加物をなるべく使用せず、果汁成分等の食物繊維成分を更に調整添加した粉末を、混和し、流動層造粒手法により、均一な粒径と成分を備えた粉末、又は顆粒を形成する。 Example 4 contains about 10% to 50% soy hypocotyl extract powder containing a large amount of isoflavone, which is a raw material for producing equol in the intestine. Soybean hypocotyl extract has bitterness, sashimi, etc., so as to alleviate this and improve the taste and texture, use food additives as much as possible, and further adjust dietary fiber components such as fruit juice components The added powder is mixed and a powder or granule having a uniform particle size and components is formed by a fluidized bed granulation technique.

 大豆胚軸抽出物も胚軸そのものから比べれば、苦み等は緩和されるが、ヒトが安定して食する為には、更に苦み等が抑えられたまろやかな食感となることが好ましい。 Soybean hypocotyl extract also relieves bitterness compared to the hypocotyl itself, but in order for humans to eat stably, it is preferable to have a mellow texture that further reduces bitterness.

 本実施例の様に、果実食物繊維との混和粉末を更に均一な粒径、均一な成分とすることで、味覚がまろやかになり継続的に食することが可能となる。 As in this example, the powder blended with fruit dietary fiber has a more uniform particle size and a uniform component, so that the taste becomes mellow and can be continuously eaten.

実施例5
 本実施例では、下記の手順で摂取試験を実施した。
 便秘症状を示すと共に、アトピー、その他の疾患治療を行っていた被験者20名について、表1の実施例2で示す成分を有する粉末状食品を毎日(1日から複数日)摂取させた。次いで、摂取の後、その後の便通について、それぞれの被験者についてアンケート調査を行った。
Example 5
In this example, an intake test was performed according to the following procedure.
For 20 subjects who showed constipation symptoms and were treated for atopy and other diseases, powdered foods having the ingredients shown in Example 2 of Table 1 were ingested daily (from 1st to several days). Then, after ingestion, a questionnaire survey was conducted on each subject for subsequent bowel movements.

 アンケートの回答結果では、摂食開始後、20人全員に便通があり、しかも排便量、排便回数が多く、便の状態もクリーム状、バナナ状で、排便が良好な形態であった。また、何れの被験者も、継続的に食しており、支障はなかった。又、摂食開始後、疾患についても、悪化することはなく、良好な便通と同様に良好な方向に向かった。便通が向上した20人について、具体的排便状況等をまとめたものが下記の表2である。 According to the results of the questionnaire, all 20 people had bowel movements after the start of eating, and the amount of bowel movements and the number of bowel movements were large. All subjects ate continuously and had no trouble. In addition, after the start of feeding, the disease did not worsen, and it went in the good direction as well as good bowel movements. Table 2 below summarizes the specific status of defecation for 20 people with improved bowel movements.

 表2に示す結果から、1回に4g以上のイヌリン(チコリ根由来)及び腸内細菌死菌体を含む粉末状の食品を、通常の加工食品として1日1回以上継続して食することが可能となることが判明した。 From the results shown in Table 2, continuously eating a powdered food containing at least 4 g of inulin (derived from chicory root) and enterobacterial bacterial cells at a time as a normal processed food at least once a day. Turned out to be possible.

Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002

 最後に、本発明の好ましい形態をまとめると、以下に付記するとおりである。
[付記1]
 腸内細菌が食する成分であって且つ当該成分をヒトが安定的に摂取可能な食物繊維状物よりなる腸内細菌用可食性組成物。
[付記2]
 エンテロコッカスフェカリスAD101(FERM P-20739)、ラクトバチルスロイテリAD302(FERM P-20741)又はラクトバチルスアシドフィルスAD206の熱水抽出物あるいはその組み合わせを更に含む、付記1に記載の腸内細菌用可食性組成物。
[付記3]
 前記食物繊維状物から、前記腸内細菌により短鎖脂肪酸を生成可能である、付記1に記載の腸内細菌用可食性組成物。
[付記4]
 前記食物繊維状物が、イヌリン、βーグルカン、レシチン、フルクタン及びグアーガムからなる群から選ばれた1員乃至複数員である、付記1に記載の腸内細菌用可食性組成物。
[付記5]
 前記食物繊維状物が、ごぼう、にら、菊芋、チコリ、大麦、燕麦又はグアーガムよりなる天然穀物素材の粉末又はその抽出物の粉末及びバナナ、リンゴ、マンゴー又は桃の果実粉末からなる群から選ばれた1員乃至複数員である、付記1に記載の腸内細菌用可食性組成物。
[付記6]
 前記食物繊維状物が、フコイダン、フラクトオリゴ糖、アラビノキシラン、ヘミセルロース、レバン、大豆オリゴ糖及びコンニャクグルコマンナンからなる群から選ばれた1員乃至複数員であり、且つ天然食品から抽出したものである、付記1に記載の腸内細菌用可食性組成物。
[付記7]
 前記食物繊維状物には、天然由来のガラクトオリゴ糖、フコオリゴ糖、マンノオリゴ糖、キシロオリゴ糖、シアリルオリゴ糖等のオリゴ糖組成物、フルクタン、ガラクタン、フコイダン、アラビナン、キシラン、キサンタン、ガラクツロナン、N-グリカン、О-グリカン、ヒアルロン酸、コンドロイチン、キシログルカン、アラビノガラクタン、アルギナート、カラギーナン、ガラクトマンナン、アラビノキシラン、グリコリピドグリカン、グリコプロテイングリカン、及びプロテオグリカンからなる群から選ばれた1員乃至複数員が含まれた天然食材、又は該天然食材を抽出した抽出物が含まれる、付記1に記載の腸内細菌用可食性組成物。
[付記8]
 前記食物繊維状物が、流動層造粒により均一に混和した粉末状物、顆粒状物、固形状物又は液状物のいずれかである、付記1に記載の腸内細菌用可食性組成物。
[付記9]
 酢酸、プロピオン酸、酪酸あるいはこれらのエステル又はこれらの塩を添加物として更に含む、付記1又は2に記載の腸内細菌用可食性組成物。
[付記10]
 前記食物繊維状物において、チコリ根抽出物が全体重量の25~50重量%、菊芋が2~5重量%、大麦又は燕麦が5重量%、果実果汁及び粉末が15~30重量%、腸内細菌熱水抽出物粉末が3~5重量%であって、該食物繊維状物を均一に混合し粒状化又は粉末化したものである、付記1又は2に記載の腸内細菌用可食性組成物。
[付記11]
 付記10に記載の腸内細菌用可食性組成物を含む健康食品。
[付記12]
 前記食物繊維状物を均一に混合し、得られた混合物を粒状化又は粉末化する工程を含む、付記11に記載の健康食品の製造方法。
Finally, preferable modes of the present invention are summarized as follows.
[Appendix 1]
An edible composition for enteric bacteria comprising a dietary fiber that is eatable by enteric bacteria and that can be stably consumed by humans.
[Appendix 2]
The edible composition for enteric bacteria according to appendix 1, further comprising a hot water extract of Enterococcus faecalis AD101 (FERM P-20739), Lactobacillus reuteri AD302 (FERM P-20741) or Lactobacillus acidophilus AD206 or a combination thereof .
[Appendix 3]
The edible composition for enteric bacteria according to appendix 1, wherein a short-chain fatty acid can be produced from the dietary fiber by the enteric bacteria.
[Appendix 4]
The edible composition for enteric bacteria according to appendix 1, wherein the dietary fiber is one or more members selected from the group consisting of inulin, β-glucan, lecithin, fructan, and guar gum.
[Appendix 5]
The dietary fiber is selected from the group consisting of powder of natural cereal material consisting of burdock, leek, chrysanthemum, chicory, barley, buckwheat or guar gum or powder thereof and banana, apple, mango or peach fruit powder. The edible composition for enteric bacteria according to appendix 1, wherein the edible composition is one or more members.
[Appendix 6]
The dietary fiber is one or more members selected from the group consisting of fucoidan, fructooligosaccharide, arabinoxylan, hemicellulose, levan, soybean oligosaccharide, and konjac glucomannan, and is extracted from natural foods. The edible composition for enteric bacteria according to appendix 1.
[Appendix 7]
The dietary fiber includes naturally occurring galactooligosaccharides, fuco-oligosaccharides, manno-oligosaccharides, xylo-oligosaccharides, sialyl-oligosaccharides and other oligosaccharide compositions, fructan, galactan, fucoidan, arabinan, xylan, xanthan, galacturonan, N-glycan Includes one or more members selected from the group consisting of, О-glycan, hyaluronic acid, chondroitin, xyloglucan, arabinogalactan, alginate, carrageenan, galactomannan, arabinoxylan, glycolipid glycan, glycoprotein glycan, and proteoglycan The edible composition for enteric bacteria according to appendix 1, wherein the extracted natural food or an extract obtained by extracting the natural food is included.
[Appendix 8]
The edible composition for enteric bacteria according to appendix 1, wherein the dietary fiber material is any of a powdery material, a granular material, a solid material, or a liquid material uniformly mixed by fluidized bed granulation.
[Appendix 9]
The edible composition for enteric bacteria according to appendix 1 or 2, further comprising acetic acid, propionic acid, butyric acid or an ester thereof or a salt thereof as an additive.
[Appendix 10]
In the above dietary fiber, chicory root extract is 25 to 50% by weight of the total weight, chrysanthemum rice cake is 2 to 5% by weight, barley or buckwheat is 5% by weight, fruit juice and powder is 15 to 30% by weight, intestine The edible composition for enteric bacteria according to appendix 1 or 2, wherein the bacterial hot water extract powder is 3 to 5% by weight, and the dietary fiber is uniformly mixed and granulated or powdered object.
[Appendix 11]
A health food comprising the edible composition for enteric bacteria according to appendix 10.
[Appendix 12]
The method for producing a health food according to supplementary note 11, comprising a step of uniformly mixing the dietary fiber and granulating or powdering the obtained mixture.

 本発明は、腸内フローラが食べる(資化する)に適した食物繊維及びエンテロコッカスフェカリスAD101(寄託番号P-20739)、ラクトバチルスロイテリAD302(寄託番号P-20741)、及びラクトバチルスアシドフィルスAD206の熱水抽出物(死菌体)を含む可食性組成物を、ヒトが摂取しやすい形態で提供することで、ヒトの体内での腸内フローラの多様性の増加を行うことができることから、新しい健康食品を提供する。 The present invention relates to dietary fiber suitable for intestinal flora to eat (utilize) and the heat of Enterococcus faecalis AD101 (deposit number P-20739), Lactobacillus reuteri AD302 (deposit number P-20741), and Lactobacillus acidophilus AD206. By providing an edible composition containing an aqueous extract (dead cells) in a form that is easy for humans to take, the diversity of intestinal flora in the human body can be increased, thus providing new health Provide food.

Claims (12)

 腸内細菌が食する成分であって且つ当該成分をヒトが安定的に摂取可能な食物繊維状物よりなる腸内細菌用可食性組成物。 An edible composition for enteric bacteria comprising a dietary fiber that is eaten by enteric bacteria and that can be stably consumed by humans.  エンテロコッカスフェカリスAD101(FERM P-20739)、ラクトバチルスロイテリAD302(FERM P-20741)又はラクトバチルスアシドフィルスAD206の熱水抽出物あるいはその組み合わせを更に含む、請求項1に記載の腸内細菌用可食性組成物。 The edible composition for enteric bacteria according to claim 1, further comprising a hot water extract of Enterococcus faecalis AD101 (FERM P-20739), Lactobacillus reuteri AD302 (FERM P-20741) or Lactobacillus acidophilus AD206 or a combination thereof. object.  前記食物繊維状物から、前記腸内細菌により短鎖脂肪酸を生成可能である、請求項1に記載の腸内細菌用可食性組成物。 The edible composition for enteric bacteria according to claim 1, wherein short-chain fatty acids can be produced from the dietary fiber by the enteric bacteria.  前記食物繊維状物が、イヌリン、βーグルカン、レシチン、フルクタン及びグアーガムからなる群から選ばれた1員乃至複数員である、請求項1に記載の腸内細菌用可食性組成物。 The edible composition for enteric bacteria according to claim 1, wherein the dietary fiber is one or more members selected from the group consisting of inulin, β-glucan, lecithin, fructan and guar gum.  前記食物繊維状物が、ごぼう、にら、菊芋、チコリ、大麦、燕麦又はグアーガムよりなる天然穀物素材の粉末又はその抽出物の粉末及びバナナ、リンゴ、マンゴー又は桃の果実粉末からなる群から選ばれた1員乃至複数員である、請求項1に記載の腸内細菌用可食性組成物。 The dietary fiber is selected from the group consisting of powder of natural cereal material consisting of burdock, leek, chrysanthemum, chicory, barley, buckwheat or guar gum or powder thereof and banana, apple, mango or peach fruit powder. The edible composition for enteric bacteria according to claim 1, wherein the edible composition is one or more members.  前記食物繊維状物が、フコイダン、フラクトオリゴ糖、アラビノキシラン、ヘミセルロース、レバン、大豆オリゴ糖及びコンニャクグルコマンナンからなる群から選ばれた1員乃至複数員であり、且つ天然食品から抽出したものである、請求項1に記載の腸内細菌用可食性組成物。 The dietary fiber is one or more members selected from the group consisting of fucoidan, fructooligosaccharide, arabinoxylan, hemicellulose, levan, soybean oligosaccharide, and konjac glucomannan, and is extracted from natural foods. The edible composition for enteric bacteria according to claim 1.  前記食物繊維状物には、天然由来のガラクトオリゴ糖、フコオリゴ糖、マンノオリゴ糖、キシロオリゴ糖、シアリルオリゴ糖等のオリゴ糖組成物、フルクタン、ガラクタン、フコイダン、アラビナン、キシラン、キサンタン、ガラクツロナン、N-グリカン、О-グリカン、ヒアルロン酸、コンドロイチン、キシログルカン、アラビノガラクタン、アルギナート、カラギーナン、ガラクトマンナン、アラビノキシラン、グリコリピドグリカン、グリコプロテイングリカン、及びプロテオグリカンからなる群から選ばれた1員乃至複数員が含まれた天然食材、又は該天然食材を抽出した抽出物が含まれる、請求項1に記載の腸内細菌用可食性組成物。 The dietary fiber includes naturally occurring galactooligosaccharides, fuco-oligosaccharides, manno-oligosaccharides, xylo-oligosaccharides, sialyl-oligosaccharides and other oligosaccharide compositions, fructan, galactan, fucoidan, arabinan, xylan, xanthan, galacturonan, N-glycan Includes one or more members selected from the group consisting of, О-glycan, hyaluronic acid, chondroitin, xyloglucan, arabinogalactan, alginate, carrageenan, galactomannan, arabinoxylan, glycolipid glycan, glycoprotein glycan, and proteoglycan The edible composition for enteric bacteria according to claim 1, wherein the natural food material or an extract obtained by extracting the natural food material is contained.  前記食物繊維状物が、流動層造粒により均一に混和した粉末状物、顆粒状物、固形状物又は液状物のいずれかである、請求項1に記載の腸内細菌用可食性組成物。 The edible composition for enteric bacteria according to claim 1, wherein the dietary fiber is one of a powder, a granule, a solid, and a liquid that are uniformly mixed by fluidized bed granulation. .  酢酸、プロピオン酸、酪酸あるいはこれらのエステル又はこれらの塩を添加物として更に含む、請求項1又は2に記載の腸内細菌用可食性組成物。 The edible composition for enteric bacteria according to claim 1 or 2, further comprising acetic acid, propionic acid, butyric acid or an ester thereof or a salt thereof as an additive.  前記食物繊維状物において、チコリ根抽出物が全体重量の25~50重量%、菊芋が2~5重量%、大麦又は燕麦が5重量%、果実果汁及び粉末が15~30重量%、腸内細菌熱水抽出物粉末が3~5重量%であって、該食物繊維状物を均一に混合し粒状化又は粉末化したものである、請求項1又は2に記載の腸内細菌用可食性組成物。 In the above dietary fiber, chicory root extract is 25 to 50% by weight of the total weight, chrysanthemum rice cake is 2 to 5% by weight, barley or buckwheat is 5% by weight, fruit juice and powder is 15 to 30% by weight, intestine The edible food for enteric bacteria according to claim 1 or 2, wherein the bacterial hot water extract powder is 3 to 5% by weight, and the dietary fiber is uniformly mixed and granulated or powdered. Composition.  請求項10に記載の腸内細菌用可食性組成物を含む健康食品。 A health food comprising the edible composition for enteric bacteria according to claim 10.  前記食物繊維状物を均一に混合し、得られた混合物を粒状化又は粉末化する工程を含む、請求項11に記載の健康食品の製造方法。 The method for producing a health food according to claim 11, comprising a step of uniformly mixing the dietary fiber and granulating or powdering the obtained mixture.
PCT/JP2018/012545 2017-03-28 2018-03-27 Edible composition for intestinal bacteria Ceased WO2018181380A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017062036 2017-03-28
JP2017-062036 2017-03-28

Publications (1)

Publication Number Publication Date
WO2018181380A1 true WO2018181380A1 (en) 2018-10-04

Family

ID=63677369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/012545 Ceased WO2018181380A1 (en) 2017-03-28 2018-03-27 Edible composition for intestinal bacteria

Country Status (2)

Country Link
JP (1) JP2018164453A (en)
WO (1) WO2018181380A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110089751A (en) * 2019-04-02 2019-08-06 大连双迪科技股份有限公司 Intestines arrange health care product
JP2020127392A (en) * 2019-02-12 2020-08-27 フジ日本精糖株式会社 Intestinal regulator containing inulin
CN112021561A (en) * 2020-09-22 2020-12-04 威海世纪博康海藻有限公司 Composition for regulating gastrointestinal function and application thereof, health food and preparation method thereof
CN113209141A (en) * 2021-06-16 2021-08-06 江南大学 Composition based on brown algae extract and lactobacillus reuteri and application thereof
JP2023501358A (en) * 2019-11-08 2023-01-18 バイオガイア エイビー Serotonin-producing bacteria

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7311336B2 (en) * 2019-07-09 2023-07-19 帝人株式会社 Composition for promoting intestinal short-chain fatty acid production
JP7449060B2 (en) * 2019-09-20 2024-03-13 株式会社桃谷順天館 Composition for improving skin quality
JP2022048629A (en) * 2020-09-15 2022-03-28 帝人株式会社 Composition for improving antibiotic-induced intestinal disbiosis
JP2022068778A (en) * 2020-10-22 2022-05-10 兵庫県公立大学法人 Composition for promoting intestinal short-chain fatty acid production and foods and drinks containing it
KR102614356B1 (en) * 2021-02-23 2023-12-14 주식회사 핏나인코리아 Diet food composition for improving bowel movements containing natural substances as an active ingredient

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS615022A (en) * 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd Ameliorant of enterobacterial flora
JP2007320946A (en) * 2006-06-05 2007-12-13 Advance Co Ltd Composition for ameliorating intestinal flora
JP2009517032A (en) * 2005-11-23 2009-04-30 ザ・コカ−コーラ・カンパニー High intensity sweetener composition containing probiotic / prebiotic and composition sweetened thereby
JP2010521136A (en) * 2007-03-16 2010-06-24 キリンホールディングス株式会社 Composition for improving intestinal flora

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL231080B1 (en) * 2010-07-28 2019-01-31 Adam Kiciak Use of a mixture of probiotic bacteria and short chain organic fatty acids (SCFA), for the production of the preparation to maintain the bacterial and acid-base homeostasis of the lower section of gastrointestinal tract in monogastric animals, including human small and large intestines
ITRM20120084A1 (en) * 2012-03-07 2013-09-08 Aboca Spa Societa Agricola PREBIOTIC MIXTURE.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS615022A (en) * 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd Ameliorant of enterobacterial flora
JP2009517032A (en) * 2005-11-23 2009-04-30 ザ・コカ−コーラ・カンパニー High intensity sweetener composition containing probiotic / prebiotic and composition sweetened thereby
JP2007320946A (en) * 2006-06-05 2007-12-13 Advance Co Ltd Composition for ameliorating intestinal flora
JP2010521136A (en) * 2007-03-16 2010-06-24 キリンホールディングス株式会社 Composition for improving intestinal flora

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLACK, A. BRENNA ET AL.: "Structural Identification of Novel Oligosaccharides Produced by Lactobacillus bulgaricus and Lactobacillus plantarum", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 60, no. 19, 2012, pages 4886 - 4894, XP055550860, ISSN: 0021-8561 *
SHIMADA, TAKASHI ET AL.: "Action of antibiotics, administered into mouse, on enterobacterial flora and serum antibody, and mitigation action thereof using lactobacillus FK-23 bacteria extract (LFK", JAPANESE JOURNAL OF ALLERGOLOGY, vol. 53, no. 2/3, 2004, pages 291, ISSN: 0021-4884 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020127392A (en) * 2019-02-12 2020-08-27 フジ日本精糖株式会社 Intestinal regulator containing inulin
CN110089751A (en) * 2019-04-02 2019-08-06 大连双迪科技股份有限公司 Intestines arrange health care product
JP2023501358A (en) * 2019-11-08 2023-01-18 バイオガイア エイビー Serotonin-producing bacteria
JP7649782B2 (en) 2019-11-08 2025-03-21 バイオガイア エイビー Serotonin-producing bacteria
CN112021561A (en) * 2020-09-22 2020-12-04 威海世纪博康海藻有限公司 Composition for regulating gastrointestinal function and application thereof, health food and preparation method thereof
CN113209141A (en) * 2021-06-16 2021-08-06 江南大学 Composition based on brown algae extract and lactobacillus reuteri and application thereof

Also Published As

Publication number Publication date
JP2018164453A (en) 2018-10-25

Similar Documents

Publication Publication Date Title
WO2018181380A1 (en) Edible composition for intestinal bacteria
Tester et al. Glucomannans and nutrition
Qiang et al. Health benefit application of functional oligosaccharides
Patel et al. The current trends and future perspectives of prebiotics research: a review
Mehta et al. Novel trends in development of dietary fiber rich meat products—a critical review
EP1465505B1 (en) Stimulation of the immune system with polydextrose
KR101619147B1 (en) Composition for preventing or improving constipation or obesity containing pear dietary fiber
CN106690331A (en) Kelp dietary fiber granules and preparation method thereof
CN108125094A (en) A kind of purposes of preparation and its blood lipid-reducing blood sugar-decreasing based on resistant starch composite dietary solid beverage
CN107440121A (en) A kind of Single Obesity tailored version clinical nutrition formula and preparation method thereof
Katke et al. Review on Psyllium husk (Plantago ovata): a novel superfood for human health
CN116349891A (en) A composition with targeted multi-effect sugar control and fat control functions, its preparation method and application
CN115671132B (en) Composition of probiotics and prebiotics and application thereof
KR100787554B1 (en) Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
Giacco et al. Functional Foods: Can Food Technology Help in the Prevention and Treatment of Diabetes?
JP2015514411A (en) Combination of β-glucan and arabinoxylan
CN107950864A (en) A kind of symphysis unit paddy vegetable meal replacement powder and its preparation method and application
Haque et al. Functional Aspects of Dietary Fibers in Nutraceuticals
KR20160113867A (en) Composition for improving constipation and health food prepared thereof
KR102609638B1 (en) Composition comprising underia pinnatifida sporophyll hot-water extract for improving gut microbiome
JP7216260B2 (en) Composition for promoting growth of Coprococcus spp.
Cozzolino et al. Functional food: Product development and health benefits
JP2003339350A (en) Diet food
KR20150010034A (en) Composition of Seaweed-ear Tea
CN110050839A (en) A kind of prebiotic black juice of plant and preparation method thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18774331

Country of ref document: EP

Kind code of ref document: A1